

## Author index\*

### A

Aalto T (see Wachtell et al). 2002;143:319-26  
Abernethy DR (see Freedman et al). 2002;143:87-94  
Acampora D (see Vaccarino et al). 2002;143:1058-67  
Acedo M, Foody JM, Pearce GL, Sprecher DL. Fibrinogen: associations with cardiovascular events in an outpatient clinic. 2002;143: 277-82  
Acedo M, Sprecher DL, Lauer MS, Francis G. Routine statin treatment after acute coronary syndromes? 2002;143:940-2 (Editorial)  
Ades PA, Savage PD, Tischler MD, Poehlman ET, Dee J, Nigell J. Determinants of disability in older coronary patients. 2002;143: 151-6  
AFFIRM Investigators. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. 2002;143:991-1001  
Ahlberg AW (see Thompson et al). 2002;143:249-56  
Aizawa T (see Tamai et al). 2002;143:506-13  
Akbari A (see Hoffman et al). 2002;143:15-21 (Trial design)  
Albini A (see Jeremias et al). 2002;143:1040-5  
Alderman M (see Aurigemma et al). 2002;143:546-51  
Aldrich HR (see Santo-Tomas et al). 2002;143:83-6  
Alhaddad IA (see Vashist et al). 2002;143:559-64 (Curriculum cardiol.)  
Almeria C (see Zamorano et al). 2002;143:157-62  
Alonso JJ (see Muñoz et al). 2002;143:620-6  
André B (see Diderholm et al). 2002;143:760-7  
Andrews J (see French et al). 2002;143:205-71  
Antman EM, McCabe CH, Braunwald E, TIMI 8 Investigators. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. 2002;143:229-34  
Antman EM (see Becker et al). 2002;143:753-9  
Antman EM (see Cohen et al). 2002;143:63-9  
Antman EM (see Sabatine et al). 2002;143:966-70  
Aoi N (see Nakayama et al). 2002;143:797-801  
Arbab-Zadeh A, Bhargava V, Russo RJ, Levin CS, Jani SK, Lucisano J, Teirstein PS. Centered versus noncentered source for intracoronary artery radiation therapy: a model based on the Scripps Trial. 2002;143:342-8  
Arena R, Humphrey R. Comparison of ventilatory expired gas parameters used to predict hospitalization in patients with heart failure. 2002;143:427-32  
Armstrong PW (see Mahaffey et al). 2002;143:242-8  
Arnett DK (see Tang et al). 2002;143:854-60  
Arnold A (see Milner et al). 2002;143:283-8  
Arora U (see Kleiman et al). 2002;143:585-93  
Arrowood JA (see Kontos et al). 2002;143:659-67  
Ascenso MC (see Morales et al). 2002;143:1101-6  
ATLAST Investigators (see Berger et al). 2002;143:841-6  
Atwood E (see Lipinski et al). 2002;143:650-8  
Atz AM (see Hoffman et al). 2002;143:15-21 (Trial design)  
Auricchio A (see Breithardt et al). 2002;143:34-44  
Aurigemma GP, Devereux RB, de Simone G, Roman MJ, O'Grady MJ, Koren M, Alderman M, Laragh J. Myocardial function and geometry in hypertensive subjects with low levels of afterload. 2002; 143:546-51  
AVID Investigators (see Cook et al). 2002;143:821-6  
Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators (see Page et al). 2002;143:643-9

### B

Badaracco JR (see Perna et al). 2002;143:814-20  
Badesch DB (see Langleben et al). 2002;143:e4  
Baglini R (see Petronio et al). 2002;143:334-41  
Bahit MC, Granger CB, Wallentin L. Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. 2002;143:205-16 (Curriculum cardiol.)  
Bailey JM (see Hoffman et al). 2002;143:15-21 (Trial design)

\*January, pp. 1-186; February, pp. 187-372; March, pp. 373-558; April, pp. 559-744; May pp. 745-930; June, pp. 931-1142.

Bairey Merz CN (see Holubkov et al). 2002;143:802-7  
Bakker P (see Breithardt et al). 2002;143:34-44  
Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M, Campana C, Perini G, Deorsola A, Masotti G, Tavazzi L, Maggioni AP, Italian Network on Congestive Heart Failure Investigators. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian Network on Congestive Heart Failure. 2002;143:398-405  
Balducci M (see Maresta et al). 2002;143:e5  
Ball SP (see Becker et al). 2002;143:753-9  
Balog C (see Mazur et al). 2002;143:594-601  
Balta O (see Breithardt et al). 2002;143:34-44  
Barnathan ES (see Freedman et al). 2002;143:87-94  
Barr A (see Jeejeebhoy et al). 2002;143:1092-100  
Barst RJ (see Langleben et al). 2002;143:e4  
Bart B (see Shah et al). 2002;143:111-17  
Batchelor W (see Berger et al). 2002;143:841-6  
Batchelor W (see Pasricha and Batchelor). 2002;143:4-6 (Editorial)  
Baumann M (see Groenning et al). 2002;143:923-9  
Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM, TIMI 11A Investigators. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. 2002;143:753-9  
Becker RC (see Li et al). 2002;143:725-32  
Behn F (see Läer et al). 2002;143:916-22  
Bella JN (see Wachtell et al). 2002;143:319-26  
Bellomo G (see Gianetti et al). 2002;143:467-74  
Bellows WH (see Nakai et al). 2002;143:181-6  
Bennencourt P (see Ferreira et al). 2002;143:391-7  
Benson H (see Dusek et al). 2002;143:577-84 (Trial design)  
Berdan LG (see Mahaffey et al). 2002;143:242-8  
Berger AK, Radford MJ, Krumholz HM. Cardiogenic shock complicating acute myocardial infarction in elderly patients: does admission to a tertiary center improve survival? 2002;143:768-76  
Berger AK (see Ko et al). 2002;143:475-81  
Berger RC, Mahaffey KW, Meier SJ, Buller CE, Batchelor W, Fry ETA, Zidar JP, ATLAST Investigators. Safety and efficacy of only 2 weeks of ticlodipine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. 2002;143:841-6  
Berger R (see Huelsmann et al). 2002;143:308-12  
Berthold HK (see Gouni-Berthold and Berthold). 2002;143:356-65  
Bethea CF (see Dusek et al). 2002;143:577-84 (Trial design)  
Beyar R (see Nikolsky et al). 2002;143:1017-26  
Beyersdorf F (see Brunner et al). 2002;143:1012-6  
Bhargava V (see Arbab-Zadeh et al). 2002;143:312-8  
Bigger JT Jr (see Cook et al). 2002;143:821-6  
Bliven B (see Spertus et al). 2002;143:145-50  
Blumenthal JA (see Watkins et al). 2002;143:460-6  
Bode C (see Brunner et al). 2002;143:1012-6  
Bonaduce D (see Spinelli et al). 2002;143:433-40  
Bonetti P (see Dubach et al). 2002;143:676-83  
Borch-Johnsen K (see Wachtell et al). 2002;143:319-26  
Borggrefe M (see Poerner et al). 2002;143:627-35  
Bosimini E (see Corrà et al). 2002;143:418-26  
Bouhouch R (see Rashba et al). 2002;143:541-5  
Boulos M (see Nikolsky et al). 2002;143:1017-26  
Braden GA (see Wheeler et al). 2002;143:76-82, 602-11  
Braunwald E (see Antman et al). 2002;143:229-34  
Braunwald E (see Sabatine et al). 2002;143:966-70  
Bray PF (see Wheeler et al). 2002;143:76-82  
Breithardt O-A, Stellbrink C, Franke A, Balta O, Diem BH, Bakker P, Sack S, Auricchio A. Pacing Therapies for Congestive Heart Failure Study Group, Pochet T, Salo R, Guidant Congestive Heart Failure Research Group. Acute effects of cardiac resynchronization therapy on left ventricular Doppler indices in patients with congestive heart failure. 2002;143:34-44  
Brenner SJ (see Jeremias et al). 2002;143:1040-5  
Brensingler C (see Kimmel et al). 2002;143:833-40  
Brighetti G (see Cicoira et al). 2002;143:1107-11  
Briuza M (see Perna et al). 2002;143:814-20  
Brown D (see Tsang et al). 2002;143:124-9  
Brown E Jr (see Vashist et al). 2002;143:559-64 (Curriculum cardiol.)

## Author index\*

### A

Aalto T (see Wachtell et al). 2002;143:319-26  
Abernethy DR (see Freedman et al). 2002;143:87-94  
Acampora D (see Vaccarino et al). 2002;143:1058-67  
Acedo M, Foody JM, Pearce GL, Sprecher DL. Fibrinogen: associations with cardiovascular events in an outpatient clinic. 2002;143: 277-82  
Acedo M, Sprecher DL, Lauer MS, Francis G. Routine statin treatment after acute coronary syndromes? 2002;143:940-2 (Editorial)  
Ades PA, Savage PD, Tischler MD, Poehlman ET, Dee J, Nigell J. Determinants of disability in older coronary patients. 2002;143: 151-6  
AFFIRM Investigators. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. 2002;143:991-1001  
Ahlberg AW (see Thompson et al). 2002;143:249-56  
Aizawa T (see Tamai et al). 2002;143:506-13  
Akbari A (see Hoffman et al). 2002;143:15-21 (Trial design)  
Albini A (see Jeremias et al). 2002;143:1040-5  
Alderman M (see Aurigemma et al). 2002;143:546-51  
Aldrich HR (see Santo-Tomas et al). 2002;143:83-6  
Alhaddad IA (see Vashist et al). 2002;143:559-64 (Curriculum cardiol.)  
Almeria C (see Zamorano et al). 2002;143:157-62  
Alonso JJ (see Muñoz et al). 2002;143:620-6  
André B (see Diderholm et al). 2002;143:760-7  
Andrews J (see French et al). 2002;143:205-71  
Antman EM, McCabe CH, Braunwald E, TIMI 8 Investigators. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. 2002;143:229-34  
Antman EM (see Becker et al). 2002;143:753-9  
Antman EM (see Cohen et al). 2002;143:63-9  
Antman EM (see Sabatine et al). 2002;143:966-70  
Aoi N (see Nakayama et al). 2002;143:797-801  
Arbab-Zadeh A, Bhargava V, Russo RJ, Levin CS, Jani SK, Lucisano J, Teirstein PS. Centered versus noncentered source for intracoronary artery radiation therapy: a model based on the Scripps Trial. 2002;143:342-8  
Arena R, Humphrey R. Comparison of ventilatory expired gas parameters used to predict hospitalization in patients with heart failure. 2002;143:427-32  
Armstrong PW (see Mahaffey et al). 2002;143:242-8  
Arnett DK (see Tang et al). 2002;143:854-60  
Arnold A (see Milner et al). 2002;143:283-8  
Arora U (see Kleiman et al). 2002;143:585-93  
Arrowood JA (see Kontos et al). 2002;143:659-67  
Ascenso MC (see Morales et al). 2002;143:1101-6  
ATLAST Investigators (see Berger et al). 2002;143:841-6  
Atwood E (see Lipinski et al). 2002;143:650-8  
Atz AM (see Hoffman et al). 2002;143:15-21 (Trial design)  
Auricchio A (see Breithardt et al). 2002;143:34-44  
Aurigemma GP, Devereux RB, de Simone G, Roman MJ, O'Grady MJ, Koren M, Alderman M, Laragh J. Myocardial function and geometry in hypertensive subjects with low levels of afterload. 2002; 143:546-51  
AVID Investigators (see Cook et al). 2002;143:821-6  
Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators (see Page et al). 2002;143:643-9

### B

Badaracco JR (see Perna et al). 2002;143:814-20  
Badesch DB (see Langleben et al). 2002;143:e4  
Baglini R (see Petronio et al). 2002;143:334-41  
Bahit MC, Granger CB, Wallentin L. Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. 2002;143:205-16 (Curriculum cardiol.)  
Bailey JM (see Hoffman et al). 2002;143:15-21 (Trial design)

\*January, pp. 1-186; February, pp. 187-372; March, pp. 373-558; April, pp. 559-744; May pp. 745-930; June, pp. 931-1142.

Bairey Merz CN (see Holubkov et al). 2002;143:802-7  
Bakker P (see Breithardt et al). 2002;143:34-44  
Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M, Campana C, Perini G, Deorsola A, Masotti G, Tavazzi L, Maggioni AP, Italian Network on Congestive Heart Failure Investigators. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian Network on Congestive Heart Failure. 2002;143:398-405  
Balducci M (see Maresta et al). 2002;143:e5  
Ball SP (see Becker et al). 2002;143:753-9  
Balog C (see Mazur et al). 2002;143:594-601  
Balta O (see Breithardt et al). 2002;143:34-44  
Barnathan ES (see Freedman et al). 2002;143:87-94  
Barr A (see Jeejeebhoy et al). 2002;143:1092-100  
Barst RJ (see Langleben et al). 2002;143:e4  
Bart B (see Shah et al). 2002;143:111-17  
Batchelor W (see Berger et al). 2002;143:841-6  
Batchelor W (see Pasricha and Batchelor). 2002;143:4-6 (Editorial)  
Baumann M (see Groenning et al). 2002;143:923-9  
Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM, TIMI 11A Investigators. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. 2002;143:753-9  
Becker RC (see Li et al). 2002;143:725-32  
Behn F (see Lier et al). 2002;143:916-22  
Bella JN (see Wachtell et al). 2002;143:319-26  
Bellomo G (see Gianetti et al). 2002;143:467-74  
Bellows WH (see Nakai et al). 2002;143:181-6  
Bennencourt P (see Ferreira et al). 2002;143:391-7  
Benson H (see Dusek et al). 2002;143:577-84 (Trial design)  
Berdan LG (see Mahaffey et al). 2002;143:242-8  
Berger AK, Radford MJ, Krumholz HM. Cardiogenic shock complicating acute myocardial infarction in elderly patients: does admission to a tertiary center improve survival? 2002;143:768-76  
Berger AK (see Ko et al). 2002;143:475-81  
Berger RC, Mahaffey KW, Meier SJ, Buller CE, Batchelor W, Fry ETA, Zidar JP, ATLAST Investigators. Safety and efficacy of only 2 weeks of ticlodipine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. 2002;143:841-6  
Berger R (see Huelsmann et al). 2002;143:308-12  
Berthold HK (see Gouni-Berthold and Berthold). 2002;143:356-65  
Bethea CF (see Dusek et al). 2002;143:577-84 (Trial design)  
Beyar R (see Nikolsky et al). 2002;143:1017-26  
Beyersdorf F (see Brunner et al). 2002;143:1012-6  
Bhargava V (see Arbab-Zadeh et al). 2002;143:312-8  
Bigger JT Jr (see Cook et al). 2002;143:821-6  
Bliven B (see Spertus et al). 2002;143:145-50  
Blumenthal JA (see Watkins et al). 2002;143:460-6  
Bode C (see Brunner et al). 2002;143:1012-6  
Bonaduce D (see Spinelli et al). 2002;143:433-40  
Bonetti P (see Dubach et al). 2002;143:676-83  
Borch-Johnsen K (see Wachtell et al). 2002;143:319-26  
Borggrefe M (see Poerner et al). 2002;143:627-35  
Bosimini E (see Corrà et al). 2002;143:418-26  
Bouhouc R (see Rashba et al). 2002;143:541-5  
Boulos M (see Nikolsky et al). 2002;143:1017-26  
Braden GA (see Wheeler et al). 2002;143:76-82, 602-11  
Braunwald E (see Antman et al). 2002;143:229-34  
Braunwald E (see Sabatine et al). 2002;143:966-70  
Bray PF (see Wheeler et al). 2002;143:76-82  
Breithardt O-A, Stellbrink C, Franke A, Balta O, Diem BH, Bakker P, Sack S, Auricchio A. Pacing Therapies for Congestive Heart Failure Study Group, Pochet T, Salo R, Guidant Congestive Heart Failure Research Group. Acute effects of cardiac resynchronization therapy on left ventricular Doppler indices in patients with congestive heart failure. 2002;143:34-44  
Brenner SJ (see Jeremias et al). 2002;143:1040-5  
Brensing C (see Kimmel et al). 2002;143:833-40  
Brighetti G (see Cicora et al). 2002;143:1107-11  
Briuza M (see Perna et al). 2002;143:814-20  
Brown D (see Tsang et al). 2002;143:124-9  
Brown E Jr (see Vashist et al). 2002;143:559-64 (Curriculum cardiol.)

Brown-Mahoney C (see Wood et al). 2002;143:176-80  
Browning A (see Kleiman et al). 2002;143:585-93  
Bruckman D (see Doughty et al). 2002;143:56-62  
Brundage BH (see LaMont et al). 2002;143:861-7  
Brunner M, Hess B, Lutter G, Zippel M, Grom A, Beyersdorf F, Bode C, Zehender M. Transmyocardial laser revascularization and left ventricular reduction surgery affect ventricular arrhythmias and heart rate variability. 2002;143:1012-6  
Brush JE Jr. An interventional cardiologist: a cardiologist who intervenes. 2002;143:943-4 (Editorial)  
Budoff MJ, Shokooh S, Shawelle RM, Kim HT, French WJ. Electron beam tomography and angiography: sex differences. 2002;143:877-82  
Budoff MJ (see LaMont et al). 2002;143:861-7  
Budoff MJ (see Wong et al). 2002;143:456-9  
Buerger J (see Kleiman et al). 2002;143:585-93  
Bugnard F (see Leizorovicz et al). 2002;143:301-7  
Buller CE (see Berger et al). 2002;143:841-6  
Burkhoff D (see Myers et al). 2002;143:1052-7  
Burman JF (see Dalby et al). 2002;143:e1  
Burzotta F (see Sabatier et al). 2002;143:1026-32

C

Cacciafest M (see Piccirillo et al). 2002;143:703-10  
Cain P, Napier S, Haluska B, Short L, Marwick TH. Influence of left ventricular size and hemodynamics on the systolic longitudinal myocardial Doppler velocity response to stress. 2002;143:169-75  
Calabrese E (see Tedesco et al). 2002;143:883-8  
Calabro R (see Tedesco et al). 2002;143:883-8  
Califf RM. Publication policy, informed consent, and the randomized clinical trial. 2002;143:187-8 (Editorial)  
Califf RM (see Mahaffey et al). 2002;143:242-8  
Campana C (see Baldasseroni et al). 2002;143:398-405  
Cannon CP. To cath or not to cath? That used to be the question. 2002;143:377-80 (Editorial)  
Caravelli P (see Petronio et al). 2002;143:334-41  
Carnethon MR, Liao D, Evans GW, Cascio WE, Chambless LE, Heiss G. Correlates of the shift in heart rate variability with an active postural change in a healthy population sample: the Atherosclerosis Risk In Communities study. 2002;143:808-13  
Carney RM (see Watkins et al). 2002;143:460-6  
Cascio WE (see Carnethon et al). 2002;143:808-13  
Cascio WE (see Simpson et al). 2002;143:535-40  
Catini C (see Lova et al). 2002;143:e2  
Cerqueira-Gomes M (see Ferreira et al). 2002;143:391-7  
Challie S (see Kleiman et al). 2002;143:585-93  
Chambless LE (see Carnethon et al). 2002;143:808-13  
Chang AC (see Hoffman et al). 2002;143:15-21 (Trial design)  
Chang CJ (see Lin et al). 2002;143:1002-8  
Charbonnier B (see Weber et al). 2002;143:313-18  
Charpentier PA (see Vaccarino et al). 2002;143:1058-67  
Chauhan V (see Krahm et al). 2002;143:528-34  
Chew DP (see Jeremias et al). 2002;143:1040-5  
Chiu C (see Sanatan et al). 2002;143:366-72  
Christman BW (see Langleben et al). 2002;143:e4  
Church TS, Lavie CJ, Milani RV, Kirby GS. Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease. 2002;143:349-55  
Cicora M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Zeni P, Zardini P. Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. 2002;143:1107-11  
Ciuffetti G (see Lupattelli et al). 2002;143:733-8  
Clague J (see Dalby et al). 2002;143:e1  
Clopton P (see McNairy et al). 2002;143:406-11  
Coats AJS (see Davies et al). 2002;143:441-7  
Cohen DJ (see Gibson et al). 2002;143:106-10  
Cohen EA (see Gibson et al). 2002;143:106-10  
Cohen M, Antman EM, Murphy SA, Radley D. Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes. 2002;143:63-9  
Cohen M (see Sabatine et al). 2002;143:966-70  
Cole J (see Weintraub et al). 2002;143:565-76 (Prog. cardiol.)  
Colhoun H (see Davies et al). 2002;143:441-7

Condorelli M (see Spinelli et al). 2002;143:433-40  
Connolly P (see Mahaffey et al). 2002;143:242-8  
Connolly SJ (see Dorian et al). 2002;143:984-90  
Connolly SJ (see Page et al). 2002;143:643-9  
Conti AA (see Lova et al). 2002;143:e2  
Cook JR, Rizo-Patron C, Curtis AB, Gillis AM, Bigger JT Jr, Kutalek SP, Coromilas J, Hofer BL, Powell J, Hallstrom AP, AVID Investigators. Effect of surgical revascularization in patients with coronary artery disease and ventricular tachycardia or fibrillation in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry. 2002;143:821-6  
Coromilas J (see Cook et al). 2002;143:821-6  
Corrà U, Mezzani A, Bosimini E, Scapellato F, Imperato A, Giannuzzi P. Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity. 2002;143:418-26  
Costantino G (see Lucini et al). 2002;143:977-83  
Cowper PA, DeLong ER, Peterson ED, Hannan EL, Ray KT, Racz M, Mark DB. Variability in cost of coronary bypass surgery in New York State: potential for cost savings. 2002;143:130-9  
Crow RS (see Simpson et al). 2002;143:535-40  
Crugnale S (see Desai et al). 2002;143:482-7  
Cruickshank MK (see Massel and Cruickshank). 2002;143:748-52  
CTAF Investigators (see Dorian et al). 2002;143:984-90  
Cucherat M (see Leizorovicz et al). 2002;143:301-7  
Curtis AB (see Cook et al). 2002;143:821-6

D

Dahlöf B (see Wachtell et al). 2002;143:319-26  
Dainiak S (see Vankawala et al). 2002;143:827-32  
Dalby MCD, Davidson SJ, Burman JF, Clague J, Sigwart U, Davies SW. Systemic platelet effects of contrast media: implications for cardiologic research and clinical practice. 2002;143:e1  
Dalsky WC (see Hillis et al). 2002;143:235-41  
Das S (see Doughty et al). 2002;143:56-62  
Dauerman HL, Yarzebski J, Gore JM, Lessard D, Goldberg RJ. Use of the invasive management strategy for patients with non-Q-wave myocardial infarction: An observational database report from the Worcester Heart Attack Study. 2002;143:1033-9  
Davidson SJ (see Dalby et al). 2002;143:e1  
Davies LC, Colhoun H, Coats AJ, Piepoli M, Francis DP. A noninvasive measure of baroreflex sensitivity without blood pressure measurement. 2002;143:441-7  
Davies SW (see Dalby et al). 2002;143:e1  
Dawson G (see De Lorenzo et al). 2002;143:e3  
De Carlo M (see Petronio et al). 2002;143:334-41  
De Caterina M (see Gianetti et al). 2002;143:467-74  
De Caterina R (see Gianetti et al). 2002;143:467-74  
De Caterina R (see Maresta et al). 2002;143:e5  
de la Fuente L (see Muñoz et al). 2002;143:620-6  
de Lemos JA (see Sabatine et al). 2002;143:966-70  
De Lorenzo F, Newberry D, Scully M, Kadziola Z, Dawson G, Ranall N, Saba N, Noorani A, Kashani S, Williams R, Kakkar VV. Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure. 2002;143:e3  
De Santis V (see Spinelli et al). 2002;143:433-40  
de Simone G (see Aurigemma et al). 2002;143:546-51  
Dee J (see Ades et al). 2002;143:151-6  
Deedwania P (see Spertus et al). 2002;143:636-42  
Del Sindaco D (see Pulignano et al). 2002;143:45-55  
DeLao T (see Kleiman et al). 2002;143:585-93  
Delgado J (see Zamorano et al). 2002;143:157-62  
Delle Donne MG (see Petronio et al). 2002;143:334-41  
DeLong ER (see Cowper et al). 2002;143:130-9  
Deorsola A (see Baldasseroni et al). 2002;143:398-405  
Department of Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (see Julian et al). 2002;143:1085-91  
Dernellis J, Panaretou M. Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. 2002;143:718-24  
Desai MY, Crugnale S, Mondeau J, Helin K, Mannting F. Slow upsloping ST-segment depression during exercise: does it really signify a positive stress test? 2002;143:482-7  
Detrano RC (see Wong et al). 2002;143:456-9

Devereux RB (see Aurigemma et al). 2002;143:546-51  
 Devereux RB (see Tang et al). 2002;143:854-60  
 Devereux RB (see Wachtell et al). 2002;143:319-26  
 Dewhurst TA (see Spertus et al). 2002;143:145-50  
 Di Lenarda A (see Pulignano et al). 2002;143:45-55  
 Di Salvo G (see Tedesco et al). 2002;143:883-8  
 Dias VC (see Langleben et al). 2002;143:e4  
 Diderholm E, Andrén B, Frostfeldt G, Genberg M, Jernberg T, Lagerqvist B, Lindahl B, Venge P, Wallentin L. Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram study. 2002;143:760-7  
 Diem BH (see Breithardt et al). 2002;143:34-44  
 Do D (see Lipinski et al). 2002;143:650-8  
 Donahue M (see Kandzari et al). 2002;143:217-28 (Meetings)  
 Dorian P, Paquette M, Newman D, Green M, Connolly SJ, Talajic M, Roy D, CTAF Investigators. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. 2002;143:984-90  
 Dougherty CM (see Spertus et al). 2002;143:145-50  
 Doughty M, Mehta R, Bruckman D, Das S, Karavite D, Tsai T, Eagle K. Acute myocardial infarction in the young—the University of Michigan experience. 2002;143:56-62  
 Drazner MH (see Neily et al). 2002;143:29-33  
 Dries DL (see Neily et al). 2002;143:29-33  
 Dubach P, Myers J, Bonetti P, Scherter T, Froelicher V, Wagner D, Scheidegger M, Stuber M, Luchinger R, Schwitzer J, Hess O. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. 2002;143:676-83  
 Dubroca I (see Weber et al). 2002;143:313-18  
 Duncan B (see Thompson et al). 2002;143:249-56  
 Dunn MJ (see Warraich et al). 2002;143:1076-84  
 Duran JM (see Muñoz et al). 2002;143:620-6  
 Duraz AES (see Vianna et al). 2002;143:873-6  
 Dusek JA, Sherwood JB, Friedman R, Myers P, Bethea CF, Levitsky S, Hill PC, Jain MK, Kopceky SL, Mueller PS, Lam P, Benson H, Hibberd PL. Study of the Therapeutic Effects of Intercessory Prayer (STEP): study design and research methods. 2002;143:577-84 (Trial design)  
 Dyke CK (see Mahaffey et al). 2002;143:242-8  
 Dzankic S (see Nakai et al). 2002;143:181-6

**E**

Eagle K (see Doughty et al). 2002;143:56-62  
 Eiselt M (see Läer et al). 2002;143:916-22  
 Eisenberg MJ (see Pilote et al). 2002;143:294-300  
 Eisenberg MJ (see Tsang et al). 2002;143:124-9  
 Eisenstein EL, Nelson CL, Simon TA, Smitthen Al, Lapuerta P, Mark DB. Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. 2002;143:1112-17  
 Ellenbogen KA (see Wood et al). 2002;143:176-80  
 Ellis SG (see Jeremias et al). 2002;143:1040-5  
 Ellis SG (see Mazur et al). 2002;143:594-601  
 Epstein ML (see Turner et al). 2002;143:889-93  
 Errett L (see Jeejeebhoy et al). 2002;143:1092-100  
 Ersek B (see Say et al). 2002;143:257-64  
 ESPRIT Investigators (see Maresta et al). 2002;143:e5  
 Etienne S (see Weber et al). 2002;143:313-18  
 Evans GW (see Carnethon et al). 2002;143:808-13  
 Evans JC (see Murabito et al). 2002;143:961-5  
 Every NR (see Shavelle et al). 2002;143:488-96  
 Every NR (see Weiss et al). 2002;143:140-4

**F**

Fang ZY, Marwick TH. Vascular dysfunction and heart failure: epiphrenomenon or etiologic agent? 2002;143:383-90 (Curriculum cardioli.)  
 Farias EF (see Perna et al). 2002;143:814-20  
 Farrel W (see Vankawala et al). 2002;143:827-32

Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators (see Diderholm et al). 2002;143:760-7  
 Feldman CL, Illegbusi OJ, Hu Z, Nesto R, Waxman S, Stone PH. Determination of in vivo velocity and endothelial shear stress patterns with phasic flow in human coronary arteries: a methodology to predict progression of coronary atherosclerosis. 2002;143:931-9  
 Ferguson S (see Nakai et al). 2002;143:181-6  
 Fernandes LS (see Kleiman et al). 2002;143:585-93  
 Fernandez-Aviles F (see Muñoz et al). 2002;143:620-6  
 Fernández C (see Zamorano et al). 2002;143:157-62  
 Ferraro-Borgida M (see Thompson et al). 2002;143:249-56  
 Ferreira A, Bennencourt P, Pimenta J, Fróes F, Pestana M, Soares-da-Silva P, Cerqueira-Gomes M. The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure. 2002;143:391-7  
 Fihn SD (see Spertus et al). 2002;143:145-50  
 Fisher SG (see Juliano et al). 2002;143:1085-91  
 Fletcher RD (see Juliano et al). 2002;143:1085-91  
 Foody JM (see Acevedo et al). 2002;143:277-82  
 Forbes TJ (see Turner et al). 2002;143:889-93  
 Franceschini L (see Ciciora et al). 2002;143:1107-11  
 Francis DP (see Davies et al). 2002;143:441-7  
 Francis G (see Acevedo et al). 2002;143:940-2 (Editorial)  
 Franke A (see Breithardt et al). 2002;143:34-44  
 Franklin B (see Lipinski et al). 2002;143:650-8  
 Frederick B (see Freedman et al). 2002;143:87-94  
 Freedman J, Maselli MA, Pezzullo JC, Barnathan ES, Frederick B, Jordan RE, Abernethy DR. Pharmacodynamic profile of short-term readministration of abiciximab in healthy subjects. 2002;143:87-94  
 Freedman RA (see Mann et al). 2002;143:199-204 (Trial design)  
 Freeman M (see Jeejeebhoy et al). 2002;143:1092-100  
 French JK, Andrews J, Manda SOM, Stewart RAH, McTigue JJC, White HD. Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction. 2002;143:265-71  
 French WJ (see Budoff et al). 2002;143:877-82  
 French WJ (see Shavelle et al). 2002;143:488-96  
 Fresc J (see Schuchert et al). 2002;143:1009-11  
 Frey B (see Huelmann et al). 2002;143:308-12  
 Friedman R (see Dusek et al). 2002;143:577-84 (Trial design)  
 Fróes F (see Ferreira et al). 2002;143:391-7  
 Fritz-Hansen T (see Nilsson et al). 2002;143:696-702  
 Froelicher V (see Dubach et al). 2002;143:676-83  
 Froelicher V (see Lipinski et al). 2002;143:650-8  
 Frostfeldt G (see Diderholm et al). 2002;143:760-7  
 Fry ETA (see Berger et al). 2002;143:841-6  
 Fujioka MC (see Guntheroth et al). 2002;143:868-72  
 Funk M (see Milner et al). 2002;143:283-8  
 Furman MI (see Wheeler et al). 2002;143:602-11  
 Fuzaylov SF (see Gurbel et al). 2002;143:1068-75

**G**

Gahbauer E (see Vaccarino et al). 2002;143:1058-67  
 Galli N (see Langleben et al). 2002;143:e4  
 Galli C (see Maresta et al). 2002;143:e5  
 Garcia A (see McNairy et al). 2002;143:406-11  
 Garcimartin I (see Muñoz et al). 2002;143:620-6  
 Gardetto N (see McNairy et al). 2002;143:406-11  
 Gardner EB (see Neily et al). 2002;143:29-33  
 Gattis WA (see Gurbel et al). 2002;143:1068-75  
 Gaulden L (see Gurbel et al). 2002;143:1068-75  
 Genberg M (see Diderholm et al). 2002;143:760-7  
 Gensini GF (see Lova et al). 2002;143:e2  
 Gerds E (see Wachtell et al). 2002;143:319-26  
 Gheri G (see Lova et al). 2002;143:e2  
 Giacoppe G (see Wink et al). 2002;143:514-18  
 Gianetti J, Pedrinelli R, Petracci R, Lazzarini G, De Caterina M, Bellomo G, De Caterina R. Inverse association between carotid intima-media thickness and the antioxidant lycopene in atherosclerosis. 2002;143:467-74  
 Giannuzzi P (see Corrà et al). 2002;143:418-26  
 Gibbons RJ (see Miller et al). 2002;143:904-9  
 Gibson CM, Murphy SA, Marble SJ, Cohen DJ, Cohen EA, Lui HK, Young J Jr, Kitt MM, Lorenz TJ, Tcheng JE. Relationship of crea-

tine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. 2002;143:106-10

Gibson M (see Becker et al). 2002;143:753-9

Gilligan DM (see Wood et al). 2002;143:176-80

Gillis AM (see Cook et al). 2002;143:821-6

Gimeno F (see Muñoz et al). 2002;143:620-6

Giugliano RP (see Sabatine et al). 2002;143:966-70

Gold MR (see Rashba et al). 2002;143:541-5

Goldberg RJ, Yarzebski J, Lessard D, Wu J, Gore JM. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. 2002;143:519-27

Goldberg RJ (see Dauerman et al). 2002;143:1033-9

Goldschmidt-Clermont PJ (see Kandzari and Goldschmidt-Clermont). 2002;143:950-1 (Editorial)

Golit G (see Cicora et al). 2002;143:1107-11

Gómez I (see Muñoz et al). 2002;143:620-6

Gómez Sánchez MA (see Zamorano et al). 2002;143:157-62

Gore JM (see Dauerman et al). 2002;143:1033-9

Gore JM (see Goldberg et al). 2002;143:519-27

Gorini M (see Baldasseroni et al). 2002;143:398-405

Gorini M (see Pulignano et al). 2002;143:45-55

Gouni-Berthold I, Berthold HK. Picosano: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. 2002;143:356-65

Granger CB (see Bahit et al). 2002;143:205-16 (Curriculum cardiol.)

Grassis C (see Tedesco et al). 2002;143:883-8

Green L (see Pilote et al). 2002;143:294-300

Green M (see Dorian et al). 2002;143:984-90

Grenadier E (see Nikolsky et al). 2002;143:1017-26

Groenning BA, Nilsson JC, Sondergaard L, Pedersen F, Trawinski J, Baumann M, Larsson HBW, Hildebrandt PR. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. 2002;143:923-9

Groenning BA (see Nilsson et al). 2002;143:696-702

Grollier G (see Sabatine et al). 2002;143:1026-32

Grom A (see Brunner et al). 2002;143:1012-6

Gross GJ (see Sanatani et al). 2002;143:366-72

Gruberg L (see Nikolsky et al). 2002;143:1017-26

Guidant Congestive Heart Failure Research Group (see Breithardt et al). 2002;143:344-4

Gulisano M (see Lova et al). 2002;143:e2

Guntheroth WG, Fujioka MC, Reichenbach DD. Spontaneous resolution of obstructive valvular tumors in infants. 2002;143:868-72

Gurbel PA, Gattis WA, Fuzaylov SF, Gaulden L, Hasselblad V, Serebruany VL, O'Connor CM. Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? 2002;143:1068-75

Gurbel PA, Serebruany VL. Adhesion molecules, platelet activation, and cardiovascular risk. 2002;143:196-8 (Editorial)

Gursuner M (see Say et al). 2002;143:257-64

**H**

Haase KK (see Poerner et al). 2002;143:627-35

Haber HL (see Kimmel et al). 2002;143:833-40

Hagar JM (see LaMont et al). 2002;143:861-7

Hager WD (see Vankawala et al). 2002;143:827-32

Hahn SJ (see Mann et al). 2002;143:199-204 (Trial design)

Halabi M (see Nikolsky et al). 2002;143:1017-26

Hallstrom AP (see Cook et al). 2002;143:821-6

Haluska B (see Cain et al). 2002;143:169-75

Hamilton RM (see Sanatani et al). 2002;143:366-72

Hamon M (see Sabatine et al). 2002;143:1026-32

Hannan EL (see Cowper et al). 2002;143:130-9

Harrington RA (see Mahaffey et al). 2002;143:242-8

Hasselblad V (see Gurbel et al). 2002;143:1068-75

Havrancik EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM. Spectrum of heart failure in older patients: results from the National Heart Failure Project. 2002;143:412-17

Hayakawa H (see Tamai et al). 2002;143:506-13

Hayashi K (see Shimizu et al). 2002;143:289-93, 690-5

Hayashi T (see Inoue et al). 2002;143:790-6

Hayashi T (see Shimizu et al). 2002;143:289-93

Haze K (see Tamai et al). 2002;143:506-13

Hegele RA (see Krah et al). 2002;143:528-34

Heiman F (see Maresta et al). 2002;143:e5

Heiss G (see Carnethon et al). 2002;143:808-13

Heiss G (see Simpson et al). 2002;143:535-40

Helfer SG (see McCubbin et al). 2002;143:711-17

Helin K (see Desai et al). 2002;143:482-7

Heller EN (see Vashist et al). 2002;143:559-64 (Curriculum cardiol.)

Heller GV (see Thompson et al). 2002;143:249-56

Hess B (see Brunner et al). 2002;143:1012-6

Hess O (see Dubach et al). 2002;143:676-83

Hiasa G (see Okayama et al). 2002;143:668-75

Hibberd PL (see Dusek et al). 2002;143:577-84 (Trial design)

Higenbottam TW (see Langleben et al). 2002;143:e4

Higgins SL (see Mann et al). 2002;143:199-204 (Trial design)

Hildebrandt PR (see Groenning et al). 2002;143:923-9

Hildebrandt PR (see Nilsson et al). 2002;143:696-702

Hill PC (see Dusek et al). 2002;143:577-84 (Trial design)

Hillis GS, Terregino C, Taggart P, Killian A, Zhao N, Dalsey WC, Mangione A. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. 2002;143:235-41

Hir J (see Nikolsky et al). 2002;143:1017-26

Hirooka Y (see Mohri et al). 2002;143:684-9

Hirsch AM (see Langleben et al). 2002;143:e4

Hirschfeld J (see Kimmel et al). 2002;143:833-40

Hlatky MA (see Weiss et al). 2002;143:140-4

Hodge DO (see Miller et al). 2002;143:904-9

Hofer BI (see Cook et al). 2002;143:821-6

Hoffman TM, Wernovsky G, Atz AM, Bailey JM, Akbari A, Kocsis JF, Nelson DP, Chang AC, Kulik TJ, Spray TL, Wessel DL. Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics (PRIMACORP) study. 2002;143:15-21 (Trial design)

Holubkov R, Karas RH, Pepine CJ, Rickens CR, Reicheck N, Rogers WJ, Sharaf BL, Sopko G, Bairey Merz CN, Kelsey SF, McGorray SP, Reis SE. Large brachial artery diameter is associated with angiographic coronary artery disease in women. 2002;143:802-7

Hong M-K, Park S-W, Moon D-H, Oh S-J, Kim E-H, Lee C-W, Song J-M, Kang D-H, Song J-K, Kim J-J, Park S-J. Impact of geographic miss on adjacent coronary artery segments in diffuse in-stent restenosis with radiation therapy: angiographic and intravascular ultrasound analysis. 2002;143:327-33

Honye J (see Nakayama et al). 2002;143:797-801

Hopkins PN (see Tang et al). 2002;143:854-60

Horie S (see Minai et al). 2002;143:497-505

Hsieh F-C (see Lin et al). 2002;143:1002-8

Hu Z (see Feldman et al). 2002;143:931-9

Huang ZZ (see Mann et al). 2002;143:199-204 (Trial design)

Huelsmann M, Stefanelli T, Berger R, Frey B, Pacher R. Prognostic impact of workload in patients with congestive heart failure. 2002;143:508-12

Human DG (see Sanatani et al). 2002;143:366-72

Humphrey R (see Arena and Humphrey). 2002;143:427-32

Hurley S (see Spertus et al). 2002;143:636-42

Huynh T (see Tsang et al). 2002;143:124-9

**I**

Iacono A (see Tedesco et al). 2002;143:883-8

Iarussi D (see Tedesco et al). 2002;143:883-8

Ibsen H (see Wachtell et al). 2002;143:319-26

Ichiki T (see Mohri et al). 2002;143:684-9

Ilegbusi OJ (see Feldman et al). 2002;143:931-9

Imparato A (see Corra et al). 2002;143:418-26

IN-CHF Investigators (see Pulignano et al). 2002;143:45-55

Ino H (see Shimizu et al). 2002;143:289-93, 690-5

Inoue M (see Shimizu et al). 2002;143:289-93

Inoue T, Sakuma M, Yaguchi I, Mizoguchi K, Uchida T, Takayanagi K, Hayashi T, Morooka S. Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. 2002;143:790-6

Iraavedra M (see Morales et al). 2002;143:1101-6

Ishihara M (see Kurisaki et al). 2002;143:448-55

Italian Network on Congestive Heart Failure Investigators (see Baldasseroni et al). 2002;143:398-405

Ito S (see Matsuoka et al). 2002;143:552-8

Itoh H (see Shimizu et al). 2002;143:690-5

Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN, Department of Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. QRS duration and mortality in patients with congestive heart failure. 2002;143:1085-91

Iwaki T (see Shimizu et al). 2002;143:690-5

Iwasaki T (see Tateishi et al). 2002;143:272-6

J

Jääskeläinen P (see Kärkkäinen et al). 2002;143:e6

Jain MK (see Dusek et al). 2002;143:577-84 (Trial design)

Jani SK (see Arbab-Zadeh et al). 2002;143:342-8

Jantus E (see Perna et al). 2002;143:814-20

Jeejeebhoy F, Keith M, Freeman M, McCall M, Kurian R, Mazer D, Errett L. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. 2002;143:1092-100

Jensen GB (see Nilsson et al). 2002;143:696-702

Jeremias A, Albrini A, Ziada KM, Chew DP, Brener SJ, Topol EJ, Ellis SG. Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction. 2002;143:1040-5

Jernberg T (see Diderholm et al). 2002;143:760-7

Jesse RL (see Kontos et al). 2002;143:70-5, 659-67

Jollis JK (see Nash and Jollis). 2002;143:745-7 (Editorial)

Jones J (see Myers et al). 2002;143:1052-7

Jones P (see Spertus et al). 2002;143:636-42

Jordan RE (see Freedman et al). 2002;143:87-94

Joseph L (see Pilote et al). 2002;143:294-300

K

Kadziola Z (see De Lorenzo et al). 2002;143:e3

Kahn JK, O'Neill WW. Two vessels or not two vessels? That is the question. 2002;143:948-9 (Editorial)

Kakkar VV (see De Lorenzo et al). 2002;143:e3

Kaluzza GL (see Mazur et al). 2002;143:594-601

Kamalesh M, Matorin R, Sawada S. Prognostic value of a negative stress echocardiographic study in diabetic patients. 2002;143:163-8

Kandzari DE, Goldschmidt-Clermont PJ. Making positive out of negative trials. 2002;143:950-1 (Editorial)

Kandzari DE, Kay J, O'Shea JC, Trichon BH, Donahue M, Liao L, Rao SV. Highlights from the American Heart Association Annual Scientific Sessions 2001: November 11 to 14, 2001. 2002;143:217-28 (Meetings)

Kaneda T (see Shimizu et al). 2002;143:289-93

Kaneko Y (see Nakayama et al). 2002;143:797-801

Kang D-H (see Hong et al). 2002;143:327-33

Kanmatsuse K (see Nakayama et al). 2002;143:797-801

Kanmatsuse K (see Tamai et al). 2002;143:506-13

Karas RH (see Holubkov et al). 2002;143:802-7

Karasik PE (see Iuliano et al). 2002;143:1058-91

Karavite D (see Doughty et al). 2002;143:56-62

Kärkkäinen P (see Kärkkäinen et al). 2002;143:e6

Kärkkäinen S, Peuhkurinen K, Jääskeläinen P, Miettinen R, Kärkkäinen P, Kuusisto J, Laakso M. No variants in the cardiac actin gene in Finnish patients with dilated or hypertrophic cardiomyopathy. 2002;143:e6

Kasac I (see Warraich et al). 2002;143:1076-84

Kashani S (see De Lorenzo et al). 2002;143:e3

Kasi SV (see Vaccarino et al). 2002;143:1058-67

Kastrati A (see Koch et al). 2002;143:971-6

Katoh K (see Tamai et al). 2002;143:506-13

Katoh O (see Tamai et al). 2002;143:506-13

Katz AM (see Vankawala et al). 2002;143:827-32

Kawada H (see Okayama et al). 2002;143:668-75

Kawagoe T (see Kurisu et al). 2002;143:448-55

Kay J (see Kandzari et al). 2002;143:217-28 (Meetings)

Kazanegara P (see McNairy et al). 2002;143:406-11

Keith M (see Jeejeebhoy et al). 2002;143:1092-100

Kelsey SF (see Holubkov et al). 2002;143:802-7

Kereiakes DJ (see Mazur et al). 2002;143:594-601

Kereiakes DJ (see Wheeler et al). 2002;143:602-11

Khan IA. Long QT syndrome: diagnosis and management. 2002;143:7-14 (Curriculum cardiol.)

Killian A (see Hillis et al). 2002;143:235-41

Kim E-H (see Hong et al). 2002;143:327-33

Kim HT (see Budoff et al). 2002;143:877-82

Kim J-J (see Hong et al). 2002;143:327-33

Kimmel SE, Sauer WH, Brensinger C, Hirshfeld J, Haber HL, Localio AR. Relationship between coronary angioplasty laboratory volume and outcomes after hospital discharge. 2002;143:833-40

King J (see Wink et al). 2002;143:514-18

Kinoshita M (see Minai et al). 2002;143:497-505

Kirby GS (see Church et al). 2002;143:349-55

Kitt MM (see Gibson et al). 2002;143:106-10

Kitzman DW (see Tang et al). 2002;143:854-60

Kiyama M (see Shimizu et al). 2002;143:289-93

Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buerger J, Mathew S, Browning A, DeLao T. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. 2002;143:585-93

Kleiman NS (see Lincoff et al). 2002;143:847-53

Kleiman NS (see Mahaffey et al). 2002;143:242-8

Kleiman NS (see Mazur et al). 2002;143:594-601

Klein GJ (see Krahn et al). 2002;143:528-34

Klein N (see Seyfarth et al). 2002;143:118-23

Klein RC (see Mann et al). 2002;143:199-204 (Trial design)

Klem E (see Kleiman et al). 2002;143:585-93

Klem J (see Kleiman et al). 2002;143:585-93

Kloda E. Recertification: nobody asked me! 2002;143:946-7 (Editorial)

Kneussl M (see Langleben et al). 2002;143:e4

Knoepfelmacher M (see Vianna et al). 2002;143:873-6

Ko D, Wang Y, Berger AK, Radford MJ, Krumholz HM. Nonsteroidal antiinflammatory drugs after acute myocardial infarction. 2002;143:475-81

Koch W, Kastrati A, Mehilli J, von Beckerath N, Schömöig A. CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction. 2002;143:971-6

Kocsis JF (see Hoffman et al). 2002;143:15-21 (Trial design)

Koksch M (see Seyfarth et al). 2002;143:118-23

Kokubun S (see Nakayama et al). 2002;143:797-801

Konno T (see Shimizu et al). 2002;143:690-5

Kono Y (see Kurisu et al). 2002;143:448-55

Kontos MC, Kurdziel K, McQueen R, Arrowood JA, Jesse RL, Ornato JP, Paulson WHP, Tatum JL, Nixon JV. Comparison of 2-dimensional echocardiography and myocardial perfusion imaging for diagnosing myocardial infarction in emergency department patients. 2002;143:659-67

Kontos MC, Ornato JP, Schmidt KL, Tatum JL, Jesse RL. Incidence of high-risk acute coronary syndromes and eligibility for glycoprotein IIb/IIIa inhibitors among patients admitted for possible myocardial ischemia. 2002;143:70-5

Kopecky SL (see Dusek et al). 2002;143:577-84 (Trial design)

Korducki L (see Langleben et al). 2002;143:e4

Koren M (see Aurigemma et al). 2002;143:546-51

Kosuge K (see Nakayama et al). 2002;143:797-801

Kottke-Marchant K (see Lincoff et al). 2002;143:847-53

Kottke-Marchant K (see Wheeler et al). 2002;143:602-11

Krahn AD, Yee R, Chauhan V, Skanes AC, Wang J, Heggele RA, Klein GJ. Beta blockers normalize QT hysteresis in long QT syndrome. 2002;143:528-34

Kralev S (see Poerner et al). 2002;143:627-35

Kramer CM, Malkowski MJ, Mankad S, Theobald TM, Pakstis DL, Rogers WJ Jr. Magnetic resonance tagging and echocardiographic response to dobutamine and functional improvement after reperfused myocardial infarction. 2002;143:1046-51

Krishnaswamy P (see McNairy et al). 2002;143:406-11

Kroll CR, Ohman EM. Should reperfusion strategies in myocardial infarction be modified for the very elderly? 2002;143:373-6 (Editorial)

Krumholz HM (see Berger et al). 2002;143:768-76

Krumholz HM (see Havranek et al). 2002;143:412-17

Krumholz HM (see Ko et al). 2002;143:475-81

Krumholz HM (see Vaccarino et al). 2002;143:1058-67

Kuhl U (see Warraich et al). 2002;143:1076-84

Kulik TJ (see Hoffman et al). 2002;143:15-21 (Trial design)

Kunimoto M (see Nakayama et al). 2002;143:797-801  
Kurdziel K (see Kontos et al). 2002;143:659-67  
Kurian R (see Jeejeebhoy et al). 2002;143:1092-100  
Kurisu S, Sato H, Kawagoe T, Ishihara M, Shimatani Y, Nishioka K, Kono Y, Umemura T, Nakamura S. Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction. 2002;143:448-55  
Kutalek SP (see Cook et al). 2002;143:821-6  
Kuusisto J (see Kärkkäinen et al). 2002;143:e6  
Kyotani S (see Oya et al). 2002;143:739-44

L

Laakso M (see Kärkkäinen et al). 2002;143:e6  
Läer S, Mir TS, Behn F, Eiselt M, Scholz H, Venzke A, Meibohm B, Weil J. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. 2002;143:916-22  
Lagerqvist B (see Diderholm et al). 2002;143:760-7  
Lam P (see Dusek et al). 2002;143:577-84 (Trial design)  
Lama G (see Tedesco et al). 2002;143:883-8  
Lamas GA (see Santo-Tomas et al). 2002;143:83-6  
LaMont DH, Budoff MJ, Shavelle DM, Shavelle R, Brundage BH, Hagar JM. Coronary calcium scanning adds incremental value to patients with positive stress tests. 2002;143:861-7  
Langleben D, Christman BW, Barsi RJ, Dias VC, Gallo N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Soler M. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. 2002;143:e4  
Lapuerta P (see Eisenstein et al). 2002;143:1112-17  
Laragh J (see Aurigemma et al). 2002;143:546-51  
Larson MG (see Murabito et al). 2002;143:961-5  
Larsson HBW (see Grønning et al). 2002;143:923-9  
Larsson HBW (see Nilsson et al). 2002;143:696-702  
Latsch A (see Poerner et al). 2002;143:627-35  
Lauer MS (see Acevedo et al). 2002;143:940-2 (Editorial)  
Lavezzari M (see Maresta et al). 2002;143:e5  
Lavie CJ (see Church et al). 2002;143:349-55  
Lavie CJ (see Lucini et al). 2002;143:977-83  
Lazzerini G (see Gianetti et al). 2002;143:467-74  
Lechat P (see Leizorovicz et al). 2002;143:301-7  
Lecluse E (see Sabatier et al). 2002;143:1026-32  
Lee C-N (see Lin et al). 2002;143:1002-8  
Lee CW (see Hong et al). 2002;143:327-33  
Lee KL (see Mahaffey et al). 2002;143:242-8  
Lee RJ (see Nakai et al). 2002;143:181-6  
Leggio F (see Pulignano et al). 2002;143:45-55  
Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies—CIBIS and CIBIS II. 2002;143:301-7  
LESS Investigators (see Mann et al). 2002;143:199-204 (Trial design)  
Lessard D (see Dauer et al). 2002;143:1033-9  
Lessard D (see Goldberg et al). 2002;143:519-27  
Leung JM (see Nakai et al). 2002;143:181-6  
Levin CS (see Arbab-Zadeh et al). 2002;143:342-8  
Levitsky S (see Dusek et al). 2002;143:577-84 (Trial design)  
Levy D (see Murabito et al). 2002;143:961-5  
Levy RD (see Langleben et al). 2002;143:e4  
Li YF, Spencer FA, Becker RC. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition. 2002;143:725-32  
Liao D (see Carnethon et al). 2002;143:808-13  
Liao L (see Kandzari et al). 2002;143:217-28 (Meetings)  
Liberman B (see Vianna et al). 2002;143:873-6  
Lieberman EH (see Santo-Tomas et al). 2002;143:83-6  
Limbruno U (see Petronio et al). 2002;143:334-41  
Lin J-H, Chang C-I, Wang J-K, Wu M-H, Shyu M-K, Lee C-N, Lue H-C, Hsieh F-C. Intrauterine diagnosis of heterotaxy syndrome. 2002;143:1002-8  
Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percu-

taneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). 2002;143:847-53

Lincoff AM (see Mazur et al). 2002;143:594-601  
Lindahl B (see Diderholm et al). 2002;143:760-7  
Linn S (see Nikolsky et al). 2002;143:1017-26  
Lionetti M (see Piccirillo et al). 2002;143:703-10  
Lipinski M, Froelicher V, Atwood E, Tseitlin A, Franklin B, Osterberg L, Do D, Myers J. Comparison of treadmill scores with physician estimates of diagnosis and prognosis in patients with coronary artery disease. 2002;143:650-8

Localio AR (see Kimmel et al). 2002;143:833-40  
Lopez-Jimenez F (see Santo-Tomas et al). 2002;143:83-6  
Lorenz TJ (see Gibson et al). 2002;143:106-10

Lova RM, Miniti B, Macchi C, Gulisano M, Gheri G, Catini C, Conti AA, Gensini GF. Morphologic changes in the microcirculation induced by chronic smoking habit: a videocapillaroscopic study on the human labial mucosa. 2002;143:e2

Lozano J (see Morales et al). 2002;143:1101-6

Lucci D (see Baldasseroni et al). 2002;143:398-405  
Lucci D (see Pulignano et al). 2002;143:45-55

Luchinger R (see Dubach et al). 2002;143:676-83

Lucini D, Milani RV, Costantino G, Lavie CJ, Porta A, Pagani M. Effects of cardiac rehabilitation and exercise training on autonomic regulation in patients with coronary artery disease. 2002;143:977-83

Lucisano J (see Arbab-Zadeh et al). 2002;143:342-8

Lue H-C (see Lin et al). 2002;143:1002-8

Lui HK (see Gibson et al). 2002;143:106-10

Lupattelli G, Pasqualini L, Siepi D, Marchesi S, Pirro M, Vaudo G, Ciuffetti G, Mannarino E. Increased postprandial lipemia in patients with normolipemic peripheral arterial disease. 2002;143:73-8

Lutter G (see Brunner et al). 2002;143:1012-6

M

Mabuchi H (see Shimizu et al). 2002;143:289-93, 690-5

Macchi C (see Lova et al). 2002;143:e2

Machado H (see Santo-Tomas et al). 2002;143:83-6

Macin SM (see Perna et al). 2002;143:814-20

MacMurdy KA (see Rashba et al). 2002;143:541-5

Mady C (see Vianna et al). 2002;143:873-6

Maestre M (see Morales et al). 2002;143:1101-6

Maggioni AP (see Baldasseroni et al). 2002;143:398-405

Maggioni AP (see Pulignano et al). 2002;143:45-55

Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califff RM, Harrington RA, PARAGON-B Investigators. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. 2002;143:242-8

Mahaffey KW (see Berger et al). 2002;143:841-6

Mahoney E (see Spertus et al). 2002;143:636-42

Maierson ES (see Lincoff et al). 2002;143:847-53

Maisel AS (see McNairy et al). 2002;143:406-11

Mak KH (see Tsang et al). 2002;143:124-9

Malkowski MJ (see Kramer et al). 2002;143:1046-51

Manda SOM (see French et al). 2002;143:265-71

Mangione A (see Hillis et al). 2002;143:235-41

Mankad S (see Kramer et al). 2002;143:1046-51

Mann DE, Klein RC, Higgins SL, Freedman RA, Hahn SJ, Huang ZZ, LESS Investigators. The Low Energy Safety Study (LESS): rationale, design, patient characteristics, and device utilization. 2002;143:199-204 (Trial design)

Mannarino E (see Lupattelli et al). 2002;143:733-8

Mannting F (see Desai et al). 2002;143:482-7

Marble SJ (see Gibson et al). 2002;143:106-10

Marcello SR (see Page et al). 2002;143:643-9

Marchesi S (see Lupattelli et al). 2002;143:733-8

Marchionni N (see Baldasseroni et al). 2002;143:398-405

Marchiniak SJ (see Wheeler et al). 2002;143:76-82

Maresh K (see Kleiman et al). 2002;143:585-93

Maresh K (see Lincoff et al). 2002;143:847-53

Marella A, Balducelli M, Varani E, Marzilli M, Galli C, Heiman F, Lavezzari M, Stragliotto E, De Caterina R, ESPRIT Investigators. Prevention of postcoronary angioplasty restenosis by omega-3

fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT). 2002;143:334-41

Mariolini M (see Petronio et al). 2002;143:334-41

Marigliano V (see Piccirillo et al). 2002;143:703-10

Marini M (see Baldasseroni et al). 2002;143:398-405

Mark DB (see Cowper et al). 2002;143:130-9

Mark DB (see Eisenstein et al). 2002;143:1112-7

Mark DB (see Mazur et al). 2002;143:594-601

Markabawi B (see Vankawala et al). 2002;143:827-32

Markiewicz W (see Nikolsky et al). 2002;143:1017-26

Martinez P (see Morales et al). 2002;143:1101-6

Marwick TH (see Cain et al). 2002;143:169-75

Marwick TH (see Fang and Marwick). 2002;143:383-90 (Curriculum cardiol.)

Marzilli M (see Maresta et al). 2002;143:e5

Mascelli MA (see Freedman et al). 2002;143:87-94

Mascelli MA (see Wheeler et al). 2002;143:76-82

Masotti G (see Baldasseroni et al). 2002;143:398-405

Masoudi FA (see Havranek et al). 2002;143:412-17

Massel D, Cruickshank MK. Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control. 2002;143:748-52

Masutani M (see Tateishi et al). 2002;143:272-6

Mathew S (see Kleiman et al). 2002;143:585-93

Mathur VS (see Tumlin et al). 2002;143:894-903

Matorin R (see Kamalesh et al). 2002;143:163-8

Matsuoka M, Oki T, Mishiro Y, Yamada H, Tabata T, Wakatsuki T, Ito S. Early systolic mitral annular motion velocities responses to dobutamine infusion predict myocardial viability in patients with previous myocardial infarction. 2002;143:552-8

Mazer M (see Jeejeebhoy et al). 2002;143:1092-100

Mazur W, Kaluza GL, Sapp S, Balog C, Topol EJ, Mark DB, Ellis SG, Kerejakes DJ, Lincoff AM, Kleiman NS. Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. 2002;143:594-601

McCabe CH (see Antman et al). 2002;143:229-34

McCabe CH (see Sabatine et al). 2002;143:966-70

McCall M (see Jeejeebhoy et al). 2002;143:1092-100

McCubbin JA, Helfer SG, Switzer FS III, Price TM. Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease. 2002;143:711-17

McDonell M (see Spertus et al). 2002;143:145-50

McGill CC (see Thompson et al). 2002;143:249-56

McGoon MD (see Langleben et al). 2002;143:e4

McGorray SP (see Holubkov et al). 2002;143:802-7

McNairy M, Gardetto N, Clopton P, Garcia A, Krishnaswamy P, Kazaanegar R, Ziegler M, Maisel AS. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. 2002;143:406-11

McQueen R (see Kontos et al). 2002;143:659-67

McTigue JJC (see French et al). 2002;143:265-71

Medina F (see Perna et al). 2002;143:814-20

Mehilli J (see Koch et al). 2002;143:971-6

Mehta R (see Doughty et al). 2002;143:56-62

Mehta S (see Langleben et al). 2002;143:e4

Meibohm B (see Lär et al). 2002;143:916-22

Meier SJ (see Berger et al). 2002;143:841-6

Meinertz T (see Schuchert et al). 2002;143:1009-11

Meroño E (see Zamorano et al). 2002;143:157-62

Mezzani A (see Corrà et al). 2002;143:418-26

Michelson AD (see Wheeler et al). 2002;143:602-11

Miettinen R (see Kärkkäinen et al). 2002;143:e6

Milani RV (see Church et al). 2002;143:349-55

Milani RV (see Lucini et al). 2002;143:977-83

Miller WL, Tointon SK, Hodge DO, Nelson SM, Rodeheffer RJ, Gibbons RJ. Long-term outcome and the use of revascularization in patients with heart failure, suspected ischemic heart disease, and large reversible myocardial perfusion defects. 2002;143:904-9

Milner KA, Funk M, Arnold A, Vaccarino V. Typical symptoms are predictive of acute coronary syndromes in women. 2002;143:283-8

Mina K, Horie H, Takahashi M, Nozawa M, Kinoshita M. Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial. 2002;143:497-505

Miniati B (see Lova et al). 2002;143:e2

Mir TS (see Lär et al). 2002;143:916-22

Mishiro Y (see Matsuoka et al). 2002;143:552-8

Miyatake K (see Oya et al). 2002;143:739-44

Mizoguchi K (see Inoue et al). 2002;143:790-6

Mogensen CE (see Wachtell et al). 2002;143:319-26

Mohri M, Ichiki T, Hirooka Y, Takeshita A. Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy. 2002;143:684-9

Moisé A (see Piccirillo et al). 2002;143:703-10

Moliterno DJ (see Wheeler et al). 2002;143:602-11

Mondeau J (see Desai et al). 2002;143:482-7

Moon D-H (see Hong et al). 2002;143:327-33

Morales FJ, Asencio MC, Oneto J, Lozano J, Otero E, Maestre M, Iraavedra M, Martínez P. Deceleration time of early filling in patients with left ventricular systolic dysfunction: functional and prognostic independent value. 2002;143:1101-6

Moreno R (see Zamorano et al). 2002;143:157-62

Morioka N (see Okayama et al). 2002;143:668-75

Morooka S (see Inoue et al). 2002;143:790-6

Morrow DA (see Sabatine et al). 2002;143:966-70

Moyna NM (see Thompson et al). 2002;143:249-56

Mueller MN (see Wheeler et al). 2002;143:602-11

Mueller PS (see Dusek et al). 2002;143:577-84 (Trial design)

Mulhern KM (see Skorton and Mulhern). 2002;143:945 (Editorial)

Munoz JC, Alonso JJ, Duran JM, Gimeno F, Ramos B, Garcimartín I, de la Fuente L, Gomez I, Fernandez-Aviles F. Coronary stent implantation in patients older than 75 years of age: clinical profile and initial and long-term (3 years) outcome. 2002;143:620-6

Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PWF. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. 2002;143:961-5

Murphy SA (see Becker et al). 2002;143:753-9

Murphy SA (see Cohen et al). 2002;143:63-9

Murphy SA (see Gibson et al). 2002;143:106-10

Murray KT (see Ray and Murray). 2002;143:381-2 (Editorial)

Murray PT (see Tumlin et al). 2002;143:894-903

Musumeci G (see Petronio et al). 2002;143:334-41

Myers J, Oesterle SN, Jones J, Burkhoff D. Do transmyocardial and percutaneous laser revascularization induce silent ischemia? An assessment by exercise testing. 2002;143:1052-7

Myers J (see Dubach et al). 2002;143:676-83

Myers J (see Lipinski et al). 2002;143:650-8

Myers P (see Dusek et al). 2002;143:577-84 (Trial design)

## N

Naeije R (see Langleben et al). 2002;143:e4

Nagata M (see Shimizu et al). 2002;143:690-5

Nagaya N (see Oya et al). 2002;143:739-44

Nakai T, Lee RJ, Schiller NB, Bellows WH, Dzankic S, Reeves J III, Romson J, Ferguson S, Leung JM. The relative importance of left atrial function versus dimension in predicting atrial fibrillation after coronary artery bypass graft surgery. 2002;143:181-6

Nakamura S (see Kuriu et al). 2002;143:448-55

Nakanishi N (see Oya et al). 2002;143:739-44

Nakanishi S (see Tamai et al). 2002;143:506-13

Nakayama T, Soma M, Saito S, Honie J, Yajima J, Rahmutula D, Kaneko Y, Sato M, Uwabo J, Aoi N, Kosuge K, Kunimoto M, Kanmatsu K, Kokubun S. Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction. 2002;143:797-801

Napier S (see Cain et al). 2002;143:169-75

Nardi C (see Petronio et al). 2002;143:334-41

Nash IS, Jollis JG. Is more better? 2002;143:745-7 (Editorial)

Naso C (see Piccirillo et al). 2002;143:703-10

Natale F (see Tedesco et al). 2002;143:883-8

National Heart Attack Alert Program (NHAAP) Coordinating Committee. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. 2002;143:777-89

Negassa A (see Yusuf and Negassa). 2002;143:22-8

Neily JB, Toto KH, Gardner EB, Rame JE, Yancy CW, Sheffield MA, Dries DL, Drazner MH. Potential contributing factors to noncom-

pliance with dietary sodium restriction in patients with heart failure. 2002;143:29-33

Nelson CL (see Eisenstein et al). 2002;143:1112-7

Nelson DP (see Hoffman et al). 2002;143:15-21 (Trial design)

Nelson SM (see Miller et al). 2002;143:904-9

Nematzadeh F (see Wood et al). 2002;143:176-80

Nester R (see Feldman et al). 2002;143:931-9

Neugebauer A (see Seyfarth et al). 2002;143:118-23

Newberry D (see De Lorenzo et al). 2002;143:e3

Newby LK (see Mahaffey et al). 2002;143:242-8

Newman D (see Dorian et al). 2002;143:984-90

Nichol P (see Spertus et al). 2002;143:145-50

Nielsen G (see Nilsson et al). 2002;143:696-702

Nieto K (see Murabito et al). 2002;143:961-5

Nigrel J (see Ades et al). 2002;143:151-6

Nikolsky E, Halabi M, Roguin A, Zdrovovych A, Gruberg L, Hir J, Grenadier E, Boulos M, Markiewicz W, Linn S, Beyar R. Staged versus one-step approach for multivessel percutaneous coronary interventions. 2002;143:1017-26

Nilsson JC, Groenning BA, Nielsen G, Fritz-Hansen T, Trawinski J, Hildebrandt PR, Jensen GB, Larsson HBW, Sondergaard L. Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. 2002;143:696-702

Nilsson JC (see Groenning et al). 2002;143:923-9

Nishikawa H (see Tamai et al). 2002;143:506-13

Nishioka K (see Kurisu et al). 2002;143:448-55

Nixon JV (see Kontos et al). 2002;143:659-67

Nocco M (see Piccirillo et al). 2002;143:703-10

Noorani A (see De Lorenzo et al). 2002;143:e3

Normand JP (see Weber et al). 2002;143:313-18

Noutsias M (see Warraich et al). 2002;143:1076-84

Novak M (see Schuchert et al). 2002;143:1009-11

Nozawa M (see Minai et al). 2002;143:497-505

○

Oberman A (see Tang et al). 2002;143:854-60

O'Connor C (see Shah et al). 2002;143:111-17

O'Connor CM (see Gurbel et al). 2002;143:1068-75

Oe K (see Shimizu et al). 2002;143:690-5

Oesterle SN (see Myers et al). 2002;143:1052-7

O'Grady MJ (see Aurigemma et al). 2002;143:546-51

Oh SJ (see Hong et al). 2002;143:327-33

Ohman EM (see Kroll and Ohman). 2002;143:373-6 (Editorial)

Ohyanagi M (see Tateishi et al). 2002;143:272-6

Okayama H, Sumimoto T, Hiasa G, Morioka N, Yamamoto K, Kawada H. Usefulness of an echo-contrast agent for assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery with transthoracic Doppler scan echocardiography. 2002;143:668-75

Okeie K (see Shimizu et al). 2002;143:690-5

Oki T (see Matsuoka et al). 2002;143:552-8

Olsen MH (see Wachtell et al). 2002;143:319-26

O'Neill WW (see Kahn and O'Neill). 2002;143:948-9 (Editorial)

Oneto J (see Morales et al). 2002;143:1101-6

Opasich C (see Baldasseroni et al). 2002;143:398-405

Opasich C (see Pulignano et al). 2002;143:45-55

Ordin DL (see Havranek et al). 2002;143:412-17

Ornat JP (see Kontos et al). 2002;143:705, 659-67

O'Shea JC (see Kandzari et al). 2002;143:217-28 (Meetings)

Osterberg L (see Lipinski et al). 2002;143:650-8

Otero E (see Morales et al). 2002;143:1101-6

Oudiz R (see Langleben et al). 2002;143:e4

Ounnoughene Z (see Weber et al). 2002;143:313-18

Oya H, Nagaya N, Uematsu M, Satoh T, Sakamaki F, Kyotani S, Sato N, Nakanishi N, Miyatake K. Poor prognosis and related factors in adults with Eisenmenger syndrome. 2002;143:739-44

○

Pacher R (see Huelsmann et al). 2002;143:308-12

Pacing Therapies for Congestive Heart Failure Study Group (see Breithardt et al). 2002;143:34-44

Pagani M (see Lucini et al). 2002;143:977-83

P

Page RL, Connolly SJ, Wilkinson WE, Marcello SR, Schnell DJ, Pritchett ELC, Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. 2002;143:643-9

Pakstis DL (see Kramer et al). 2002;143:1046-51

Palmieri V (see Wachtell et al). 2002;143:319-26

Panaretou M (see Dermelis and Panaretou). 2002;143:718-24

Pantich R (see Perna et al). 2002;143:814-20

Papademetriou V (see Wachtell et al). 2002;143:319-26

Paquette M (see Dorian et al). 2002;143:984-90

PARAGON-B Investigators (see Mahaffey et al). 2002;143:242-8

Park SJ (see Hong et al). 2002;143:327-33

Park S-W (see Hong et al). 2002;143:327-33

Parras JL (see Perna et al). 2002;143:814-20

Parsons L (see Shavelle et al). 2002;143:488-96

Parsons LS (see Weiss et al). 2002;143:140-4

Pasqualini L (see Lupattelli et al). 2002;143:733-8

Pasricha A, Batchelor W. When young hearts are broken: profiles of premature myocardial infarction. 2002;143:4-6 (Editorial)

Paterno G (see Petronio et al). 2002;143:334-41

Paulsen WHP (see Kontos et al). 2002;143:659-67

Pearce GI (see Acevedo et al). 2002;143:277-82

Pedersen F (see Groenning et al). 2002;143:923-9

Pedrinelli R (see Gianetti et al). 2002;143:467-74

Peirone A (see Sanatani et al). 2002;143:366-72

Pepine CJ (see Holubkov et al). 2002;143:802-7

Pergola V (see Tedesco et al). 2002;143:883-8

Perini G (see Baldasseroni et al). 2002;143:398-405

Perna ER, Macin SM, Parras JL, Pantich R, Farias EF, Badaracco JR, Jantus E, Medina F, Brizuela M. Cardiac troponin T levels are associated with poor short-and long-term prognosis in patients with acute cardiogenic pulmonary edema. 2002;143:814-20

Pestana M (see Ferreira et al). 2002;143:391-7

Peters RW (see Rashba et al). 2002;143:541-5

Peterson ED (see Cowper et al). 2002;143:130-9

Pettetra M (see Spinelli et al). 2002;143:433-40

Petronio AS, Musumeci G, Limbruno U, De Carlo M, Baglini R, Paterni G, Delle Donne MG, Caravelli P, Nardi C, Mariani M. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. 2002;143:334-41

Petrucchi R (see Gianetti et al). 2002;143:467-74

Peuhkuri K (see Kärkkäinen et al). 2002;143:e6

Pezzullo JC (see Freedman et al). 2002;143:87-94

Pfeffer MA (see Skali et al). 2002;143:1-3 (Editorial)

Pfeiffer D (see Seyfarth et al). 2002;143:118-23

Pfleger S (see Poerner et al). 2002;143:627-35

Piccirillo G, Nocco M, Lionetti M, Moisè A, Naso C, Marigliano V, Cacciavita M. Effects of sildenafil citrate (Viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. 2002;143:703-10

Piletti M (see Davies et al). 2002;143:441-7

Pilote L, Green L, Joseph L, Richard H, Eisenberg MJ. Antibiotics against *Chlamydia pneumoniae* and prognosis after acute myocardial infarction. 2002;143:294-300

Pimenta J (see Ferreira et al). 2002;143:391-7

Pio J (see Wong et al). 2002;143:456-9

Pirro M (see Lupattelli et al). 2002;143:733-8

Pitt B (see Spertus et al). 2002;143:636-42

Pochet T (see Breithardt et al). 2002;143:34-44

Poehlman ET (see Ades et al). 2002;143:151-6

Poerner TC, Kralev S, Voelker W, Sueselbeck T, Latsch A, Pfleger S, Schumacher B, Borggreve M, Haase KK. Natural history of small and medium-sized side branches after coronary stent implantation. 2002;143:627-35

Porcu M (see Pulignano et al). 2002;143:45-55

Porta A (see Lucini et al). 2002;143:977-83

Poston C (see Spertus et al). 2002;143:636-42

Powell J (see Cook et al). 2002;143:821-6

Price TM (see McCubbin et al). 2002;143:711-17

PRIME Investigators. Multicenter, dose-ranging study of e�egatran sulfate versus heparin with thrombolysis for acute myocardial infarction: the Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. 2002;143:95-105

Pritchett ELC (see Page et al). 2002;143:643-9

Pulignano G, Del Sindaco D, Tavazzi L, Lucci D, Gorini M, Leggio F, Porcu M, Scherillo M, Opasich C, Di Lenarda A, Senni M, Maggioni

AP, IN-CHF Investigators. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). 2002;143:45-55

## R

Racz M (see Cowper et al). 2002;143:130-9  
 Radford MJ (see Berger et al). 2002;143:768-76  
 Radford MJ (see Ko et al). 2002;143:475-81  
 Radley D (see Cohen et al). 2002;143:63-9  
 Rahmatula D (see Nakayama et al). 2002;143:797-801  
 Rame JE (see Neily et al). 2002;143:29-33  
 Ramires JAF (see Vianna et al). 2002;143:873-6  
 Ramos B (see Muñoz et al). 2002;143:620-6  
 Randall N (see De Lorenzo et al). 2002;143:e3  
 Rao DC (see Tang et al). 2002;143:85-60  
 Rao SV (see Kandzari et al). 2002;143:217-28 (Meetings)  
 Rashba EJ, Bouhouch R, MacMurdy KA, Shorofsky SR, Peters RW, Gold MR. Effect of shock polarity on the efficacy of transthoracic atrial defibrillation. 2002;143:541-5  
 Ratti G (see Tedesco et al). 2002;143:883-8  
 Rautaharju PM (see Simpson et al). 2002;143:535-40  
 Ray KT (see Cowper et al). 2002;143:130-9  
 Ray WA, Murray KT. Aspirin redundant in users of nonaspirin, nonsteroidal antiinflammatory agents? 2002;143:381-2 (Editorial)  
 Reeves J III (see Nakai et al). 2002;143:181-6  
 Reichek N (see Holubkov et al). 2002;143:802-7  
 Reichenbach DD (see Guntheroth et al). 2002;143:868-72  
 Reis SE (see Holubkov et al). 2002;143:802-7  
 Rich S (see Langleben et al). 2002;143:e4  
 Richard H (see Pilote et al). 2002;143:294-300  
 Rickens CR (see Holubkov et al). 2002;143:802-7  
 Riedel A (see Langleben et al). 2002;143:e4  
 Rizo-Patron C (see Cook et al). 2002;143:821-6  
 Robbins IM (see Langleben et al). 2002;143:e4  
 Rodeheffer RJ (see Miller et al). 2002;143:904-9  
 Roe MT (see Mahaffey et al). 2002;143:242-8  
 Roethig G (see Seyfarth et al). 2002;143:118-23  
 Rogers WJ Jr (see Kramer et al). 2002;143:1046-51  
 Rogers WJ (see Holubkov et al). 2002;143:802-7  
 Roguin A (see Nikolsky et al). 2002;143:1017-26  
 Roman MJ (see Aurigemma et al). 2002;143:546-51  
 Romson J (see Nakai et al). 2002;143:181-6  
 ROSETTA Investigators (see Tsang et al). 2002;143:124-9  
 Rossi A (see Cicoira et al). 2002;143:1107-11  
 Rother T (see Seyfarth et al). 2002;143:118-23  
 Roy D (see Dorian et al). 2002;143:984-90  
 Rubin H (see Kleiman et al). 2002;143:585-93  
 Rufilanchas JJ (see Zamorano et al). 2002;143:157-62  
 Rush JE (see Becker et al). 2002;143:753-9  
 Russo RJ (see Arbab-Zadeh et al). 2002;143:342-8

## S

Saba N (see De Lorenzo et al). 2002;143:e3  
 Sabatier R, Hamon M, Zhao QM, Burzotta F, Lecluse E, Valette B, Grollier G. Could direct stenting reduce no-reflow in acute coronary syndromes? A randomized pilot study. 2002;143:1027-32  
 Sabatine MS, McCabe CH, Morrow DA, Giugliano RP, de Lemos JA, Cohen M, Antman EM, Braunwald E. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. 2002;143:966-70  
 Sack S (see Breithardt et al). 2002;143:34-44  
 Sada MJ (see Shavelle et al). 2002;143:488-96  
 Saito S (see Nakayama et al). 2002;143:797-801  
 Sakamaki F (see Oya et al). 2002;143:739-44  
 Sakata K (see Shimizu et al). 2002;143:289-93  
 Sakuma M (see Inoue et al). 2002;143:790-6  
 Salgado LR (see Vianna et al). 2002;143:873-6  
 Salo R (see Breithardt et al). 2002;143:34-44  
 Sanatani S, Peironi A, Chiu C, Human DG, Gross GJ, Hamilton RM. Use of an implantable loop recorder in the evaluation of children with congenital heart disease. 2002;143:366-72  
 Sánchez-Harguindeguy L (see Zamorano et al). 2002;143:157-62

Sanderink G (see Becker et al). 2002;143:753-9  
 Sane DC (see Wheeler et al). 2002;143:76-82, 602-11  
 Santo-Tomas M, Lopez-Jimenez F, Machado H, Aldrich HR, Lamas GA, Lieberman EH. Effect of cigar smoking on endothelium-dependent brachial artery dilation in healthy young adults. 2002;143:83-6  
 Sapp S (see Mazur et al). 2002;143:594-601  
 Sato H (see Kurisu et al). 2002;143:448-55  
 Sato M (see Nakayama et al). 2002;143:797-801  
 Sato N (see Oya et al). 2002;143:739-44  
 Satoh T (see Oya et al). 2002;143:739-44  
 Sauer WH (see Kimmel et al). 2002;143:833-40  
 Savage PD (see Ades et al). 2002;143:151-6  
 Sawada S (see Kamalesh et al). 2002;143:163-8  
 Say AE, Gursuner M, Yazicioglu MV, Ersek B. Impact of body iron status on myocardial perfusion, left ventricular function, and angiographic morphologic features in patients with hypercholesterolemia. 2002;143:257-64  
 Scapellato F (see Corrà et al). 2002;143:418-26  
 Schechter D (see Tsang et al). 2002;143:124-9  
 Scheidegger M (see Dubach et al). 2002;143:676-83  
 Scherillo M (see Pulignano et al). 2002;143:45-55  
 Schertler T (see Dubach et al). 2002;143:676-83  
 Schiavone D (see Spinelli et al). 2002;143:433-40  
 Schiller NB (see Nakai et al). 2002;143:181-6  
 Schleicher A (see Schuchert et al). 2002;143:1009-11  
 Schmidt KL (see Kontos et al). 2002;143:70-5  
 Schnell DJ (see Page et al). 2002;143:643-9  
 Scholz H (see Lüer et al). 2002;143:916-22  
 Schömöig A (see Koch et al). 2002;143:971-6  
 Schreiner PJ (see Simpson et al). 2002;143:535-40  
 Schuchert A, Frese J, Stammwitz E, Novak M, Schleicher A, Wagner SM, Meinertz T. Low settings of the ventricular pacing output in patients dependent on a pacemaker: are they really safe? 2002;143:1009-11  
 Schultheiss HP (see Warrach et al). 2002;143:1076-84  
 Schumacher B (see Poerner et al). 2002;143:627-35  
 Schwitter J (see Dubach et al). 2002;143:676-83  
 Schwob J (see Weber et al). 2002;143:313-18  
 Scully M (see De Lorenzo et al). 2002;143:e5  
 SEAL Trial Study Team. Assessment of the safety and efficacy of the DUETT vascular hemostasis device: final results of the Safe and Effective Vascular Hemostasis (SEAL) trial. 2002;143:612-19  
 Seeberg B (see Warrach et al). 2002;143:1076-84  
 Seeger W (see Langleben et al). 2002;143:e4  
 Senni M (see Pulignano et al). 2002;143:45-55  
 Serebruany VL (see Gurbel and Serebruany). 2002;143:196-8 (Editorial)  
 Serebruany VL (see Gurbel et al). 2002;143:1068-75  
 Seyfarth H-J, Koksch M, Roethig G, Rother T, Neugebauer A, Klein N, Pfeiffer D. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. 2002;143:118-23  
 Shah BR, Velazquez E, Shaw LK, Bart B, O'Connor C, Wagner GS. Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-moderate myocardial infarcts. 2002;143:111-17  
 Sharaf BL (see Holubkov et al). 2002;143:802-7  
 Shavelle DM, Parsons L, Sada MJ, French WJ, Every NR. Is there benefit to early angiography in patients with ST-segment depression myocardial infarction? An observational study. 2002;143:488-96  
 Shavelle DM (see LaMont et al). 2002;143:861-7  
 Shavelle R (see LaMont et al). 2002;143:861-7  
 Shavelle RM (see Budoff et al). 2002;143:877-82  
 Shaw LK (see Shah et al). 2002;143:111-17  
 Sheffield MA (see Neily et al). 2002;143:29-33  
 Sheppard R (see Tsang et al). 2002;143:124-9  
 Sherppard JB (see Dusek et al). 2002;143:577-84 (Trial design)  
 Shimatani Y (see Kurisu et al). 2002;143:448-55  
 Shimizu M, Ino H, Okeie K, Yamaguchi M, Hayashi K, Nagata M, Itoh H, Iwaki T, Oe K, Konno T, Mabuchi H. Septal wall thinning and systolic dysfunction in patients with hypertrophic cardiomyopathy caused by a cardiac troponin I gene mutation. 2002;143:690-5  
 Shimizu M, Ino H, Yamaguchi M, Terai H, Hayashi K, Kiyma M, Sakata K, Hayashi T, Inoue M, Kaneda T, Mabuchi H. Chronologic electrocardiographic changes in patients with hypertrophic car-

diomyopathy associated with cardiac troponin I mutation. 2002; 143:289-93

Shokooh S (see Budoff et al). 2002;143:877-82

Shorofsky SR (see Rashba et al). 2002;143:541-5

Short L (see Cain et al). 2002;143:169-75

Shyu M-K (see Lin et al). 2002;143:1002-8

Siepi D (see Lupattelli et al). 2002;143:733-8

Sigwart U (see Dalby et al). 2002;143:e1

Silverman DI (see Vankawala et al). 2002;143:827-32

Simon TA (see Eisenstein et al). 2002;143:1112-7

Simonneau G (see Langleben et al). 2002;143:e4

Simpson RJ Jr, Cascio WE, Schreiner PJ, Crow RS, Rautaharju PM, Heiss G. Prevalence of premature ventricular contractions in a population of African American and white men and women: the Atherosclerosis Risk in Communities (ARIC) Study. 2002;143: 535-40

Singh SN (see Juliano et al). 2002;143:1085-91

Skali H, Solomon SD, Pfeffer MA. Are we asking too much of our trials? 2002;143:1-3 (Editorial)

Skanes AC (see Krahm et al). 2002;143:528-34

Skorton DJ, Mulherin KM. Recertification: mandatory or voluntary? Teaching old dogs new tricks. 2002;143:945 (Editorial)

Smitten AL (see Eisenstein et al). 2002;143:1112-7

Soares-da-Silva P (see Ferreira et al). 2002;143:391-7

Solér M (see Langleben et al). 2002;143:e4

Solomon S (see Kleiman et al). 2002;143:585-93

Solomon SD (see Skali et al). 2002;143:1-3 (Editorial)

Soma M (see Nakayama et al). 2002;143:797-801

Søndergaard L (see Groenning et al). 2002;143:923-9

Søndergaard L (see Nilsson et al). 2002;143:696-702

Song J-K (see Hong et al). 2002;143:327-33

Song J-M (see Hong et al). 2002;143:327-33

Sopko G (see Holubkov et al). 2002;143:802-7

Soletto T (see Zamorano et al). 2002;143:157-62

Sparapani R (see Mahaffey et al). 2002;143:242-8

Spencer FA (see Becker et al). 2002;143:753-9

Spencer FA (see Li et al). 2002;143:725-32

Spertus JA, Dewhurst TA, Dougherty CM, Nichol P, McDonell M, Bliven B, Fihn SD. Benefits of an "angina clinic" for patients with coronary artery disease: a demonstration of health status measures as markers of health care quality. 2002;143:145-50

Spertus JA, Tooley J, Jones P, Poston C, Mahoney E, Deedwania P, Hurley S, Pitt B, Weintraub WS. Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHEUS (Eplerenone's neurohormonal Efficacy and SUrvival Study). 2002;143:636-42

Spinelli L, Petretta M, Vicario MLE, Schiavone D, De Santis V, Bonaduce D, Condorelli M. Losartan treatment and left ventricular filling during volume loading in patients with dilated cardiomyopathy. 2002;143:433-40

Spray TL (see Hoffman et al). 2002;143:15-21 (Trial design)

Sprecher DL (see Acevedo et al). 2002;143:277-82, 940-2 (Editorial)

Stambler BS (see Wood et al). 2002;143:176-80

Stammwitz E (see Schuchert et al). 2002;143:1009-11

Stefenelli T (see Huelsmann et al). 2002;143:308-12

Steinhubl SR (see Wheeler et al). 2002;143:602-11

Stellbrink C (see Breithardt et al). 2002;143:34-44

Stewart RAH (see French et al). 2002;143:265-71

Stone PH (see Feldman et al). 2002;143:931-9

Stragliotto E (see Maresta et al). 2002;143:45

Stuber M (see Dubach et al). 2002;143:676-83

Sueselbeck T (see Poerner et al). 2002;143:627-35

Sullivan JL. Stored iron and myocardial perfusion deficits. 2002;143: 193-5 (Editorial)

Sumimoto T (see Okayama et al). 2002;143:668-75

Suzuki S (see Tamai et al). 2002;143:506-13

Suzuki T (see Tamai et al). 2002;143:506-13

Switzer FS III (see McCubbin et al). 2002;143:711-17

SYNTERGY Executive Committee. The SYNTERGY trial: study design and rationale. 2002;143:952-60 (Trial design)

Takase S (see Tamai et al). 2002;143:506-13

Takanagai K (see Inoue et al). 2002;143:790-6

Takeshita A (see Mohri et al). 2002;143:684-9

Talaiji M (see Dorian et al). 2002;143:984-90

Tamai H, Katoh K, Yamaguchi T, Hayakawa H, Kanmatsuse K, Haze K, Aizawa T, Nakanishi S, Suzuki S, Suzuki T, Takase S, Nishikawa H, Katoh O, TREAT-2 Study Investigators. The impact of traniplast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). 2002;143:506-13

Tang W, Devereux RB, Rao DC, Oberman A, Hopkins PN, Kitzman DW, Arnett DK. Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study. 2002;143:854-60

Tateishi J, Waku S, Masutani M, Ohyanagi M, Iwasaki T. Hepatocyte growth factor as a potential predictor of the presence of atherosclerotic aorto-iliac artery disease. 2002;143:272-6

Tatum JL (see Kontos et al). 2002;143:705, 659-67

Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. 2002;143:910-15

Tavazzi L (see Baldasseroni et al). 2002;143:398-405

Tavazzi L (see Pulignano et al). 2002;143:45-55

Tcheng JE (see Gibson et al). 2002;143:106-10

Tedesco MA, Di Salvo G, Natale F, Pergola V, Calabrese E, Grassia C, Ratti G, Iarussi D, Iacono A, Calabro R, Lama G. The heart in neurofibromatosis type 1: an echocardiographic study. 2002;143: 883-8

Teirstein PS (see Arbab-Zadeh et al). 2002;143:342-8

Terai H (see Shimizu et al). 2002;143:289-93

Terregino C (see Hillis et al). 2002;143:235-41

Theobald TM (see Kramer et al). 2002;143:1046-51

Thompson PD, Ahlborg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, McGill CC, Heller GV. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. 2002;143:249-56

TIMI 8 Investigators (see Antman et al). 2002;143:229-34

TIMI 11A Investigators (see Becker et al). 2002;143:753-9

Tischler MD (see Ades et al). 2002;143:151-6

Tointon SK (see Miller et al). 2002;143:904-9

Tooley J (see Spertus et al). 2002;143:636-42

Tooley JF (see Weintraub et al). 2002;143:565-76 (Prog. cardiol.)

Topol EJ (see Jeremias et al). 2002;143:1040-5

Topol EJ (see Lincoff et al). 2002;143:847-53

Topol EJ (see Mahaffey et al). 2002;143:242-8

Topol EJ (see Mazur et al). 2002;143:594-601

Toto KH (see Neily et al). 2002;143:29-33

Trawinski J (see Groenning et al). 2002;143:923-9

Trawinski J (see Nilsson et al). 2002;143:696-702

TREAT-2 Study Investigators (see Tamai et al). 2002;143:506-13

Trichon BH (see Kandzari et al). 2002;143:217-28 (Meetings)

Tsai T (see Doughty et al). 2002;143:56-62

Tsang J, Sheppard R, Mak KH, Brown D, Huynh T, Schechter D, Eisenberg MJ, ROSETTA Investigators. Six-month outcomes of percutaneous transluminal coronary angioplasty in hypertensive patients: results from the ROSETTA registry. 2002;143:124-9

Tseitlin A (see Lipinski et al). 2002;143:650-8

Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. 2002;143:894-903

Turner DR, Forbes TJ, Epstein ML, Vincent JA. Early reopening and recanalization after successful coil occlusion of the patent ductus arteriosus. 2002;143:889-93

U

Uchida T (see Inoue et al). 2002;143:790-6

Uematsu M (see Oya et al). 2002;143:739-44

Umemura T (see Kurisu et al). 2002;143:448-55

Uwabo J (see Nakayama et al). 2002;143:797-801

V

Vaccarino V, Gahbauer E, Kasl SV, Charpentier PA, Acampora D, Krumholz HM. Differences between African Americans and

whites in the outcome of heart failure: evidence for a greater functional decline in African Americans. 2002;143:1058-67

Vaccarino V (see Milner et al). 2002;143:283-8

Valette B (see Sabatier et al). 2002;143:1027-32

Vankawala V, Markabawi B, Dainiak S, Werner M, Hager WD, Farrell W, Katz AM, Silverman DI. Left ventricular function in atrial fibrillation during overdrive pacing. 2002;143:827-32

Varani E (see Maresta et al). 2002;143:655

Vashist A, Heller EN, Brown EJ Jr, Alhaddad IA. Renal artery stenosis: a cardiovascular perspective. 2002;143:559-64 (Curriculum cardiol.)

Vaudo G (see Lupattelli et al). 2002;143:733-8

Vaur L (see Weber et al). 2002;143:313-18

Velazquez E (see Shah et al). 2002;143:111-17

Venge P (see Diderholm et al). 2002;143:760-7

Venzke A (see Lier et al). 2002;143:916-22

Vianna CB, Vieira MLC, Mady C, Liberman B, Durazzo AES, Knoepfelmacher M, Salgado LR, Ramires JAF. Treatment of acromegaly improves myocardial abnormalities. 2002;143:873-6

Vicario MLE (see Spinelli et al). 2002;143:433-40

Vieira MLC (see Vianna et al). 2002;143:873-6

Vincent JA (see Turner et al). 2002;143:889-93

Voelker W (see Poerner et al). 2002;143:627-35

von Beckerath N (see Koch et al). 2002;143:971-6

## W

Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, Gerdts E, Wright JT Jr, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H, Devereux RB. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. 2002;143:319-26

Wagner D (see Dubach et al). 2002;143:676-83

Wagner GS (see Shah et al). 2002;143:111-17

Wagner SM (see Schuchert et al). 2002;143:1009-11

Wakatsuki T (see Matsuo et al). 2002;143:552-8

Waku S (see Tateishi et al). 2002;143:272-6

Wallentin L (see Bahit et al). 2002;143:205-16 (Curriculum cardiol.)

Wallentin L (see Diderholm et al). 2002;143:760-7

Wang A (see Tumlin et al). 2002;143:894-903

Wang J-K (see Lin et al). 2002;143:1002-8

Wang J (see Krahm et al). 2002;143:528-34

Wang Y (see Ko et al). 2002;143:475-81

Warrach RS, Noutsias M, Kasac I, Seeberg B, Dunn MJ, Schultheiss HP, Yacoub MH, Kuhl U. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. 2002;143:1076-84

Watkins LL, Blumenthal JA, Carney RM. Association of anxiety with reduced baroreflex cardiac control in patients after acute myocardial infarction. 2002;143:460-6

Waxman S (see Feldman et al). 2002;143:931-9

Weaver WD (see Weiss et al). 2002;143:140-4

Weber S, Vaur L, Ounnoughene Z, Schwob J, Dubroca I, Normand JP, Etienne S, Charbonnier B. Acute blood pressure response to trandolapril and captopril in patients with left ventricular dysfunction after acute myocardial infarction. 2002;143:313-18

Weil J (see Lier et al). 2002;143:916-22

Weintraub WS, Cole J, Toohey JF. Cost and cost-effectiveness studies in heart failure research. 2002;143:565-76 (Prog. cardiol.)

Weintraub WS (see Spertus et al). 2002;143:636-42

Weiss JP, Parsons LS, Every NR, Weaver WD, Hlatky MA. Does enrollment in a randomized clinical trial lead to a higher cost of routine care? 2002;143:140-4

Werner M (see Vankawala et al). 2002;143:827-32

Wernovsky G (see Hoffman et al). 2002;143:15-21 (Trial design)

Wessel DL (see Hoffman et al). 2002;143:15-21 (Trial design)

Westfall KA (see Havranek et al). 2002;143:412-17

Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC. Reduced inhibition by abciximab in platelets with the P1A<sup>2</sup> polymorphism. 2002;143:76-82

Wheeler GL, Braden GA, Steinbuhl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. 2002;143:602-11

White CM (see Thompson et al). 2002;143:249-56

White HD. Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin. 2002;143:189-92 (Editorial)

White HD (see French et al). 2002;143:265-71

Wilkinson WE (see Page et al). 2002;143:643-9

Williams R (see De Lorenzo et al). 2002;143:e3

Wilson PWF (see Murabito et al). 2002;143:961-5

Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. 2002;143:514-18

Wolfe P (see Havranek et al). 2002;143:412-17

Wolski KE (see Lineoff et al). 2002;143:847-53

Wong ND, Budoff MJ, Pio J, Detrano RC. Coronary calcium and cardiovascular event risk: evaluation by age-and sex-specific quartiles. 2002;143:456-9

Wood MA, Gilligan DM, Brown-Mahoney C, Nematzadeh F, Stambler BS, Ellenbogen KA. Clinical and electrophysiologic effects of calcium channel blockers in patients receiving ibutilide. 2002;143:176-80

Wright JT Jr (see Wachtell et al). 2002;143:319-26

Wu J (see Goldberg et al). 2002;143:519-27

Wu M-H (see Lin et al). 2002;143:1002-8

## Y

Yacoub MH (see Warrach et al). 2002;143:1076-84

Yaguchi I (see Inoue et al). 2002;143:790-6

Yajima J (see Nakayama et al). 2002;143:797-801

Yamada H (see Matsuo et al). 2002;143:552-8

Yamaguchi M (see Shimizu et al). 2002;143:289-93, 690-5

Yamaguchi T (see Tamai et al). 2002;143:506-13

Yamamoto K (see Okayama et al). 2002;143:668-75

Yancy CW (see Neily et al). 2002;143:29-33

Yarzebski J (see Dauerman et al). 2002;143:1033-9

Yarzebski J (see Goldberg et al). 2002;143:519-27

Yazicioglu MV (see Say et al). 2002;143:257-64

Yer R (see Krahm et al). 2002;143:528-34

Young J Jr (see Gibson et al). 2002;143:106-10

Yusuf S, Negassa A. Choice of clinical outcomes in randomized trials of heart failure therapies: disease-specific or overall outcomes? 2002;143:22-8

## Z

Zamorano JL, Delgado J, Almeria C, Gómez Sánchez MA, Sotelo T, Moreno R, Meroño E, Fernández C, Rufilanchas JJ, Sánchez-Harquinde L. Assessment of cardiac viability by thallium 201 redistribution and dobutamine echocardiography. 2002;143:157-62

Zanolli L (see Cicoira et al). 2002;143:1107-11

Zardini P (see Cicoira et al). 2002;143:1107-11

Zdrovová A (see Nikolsky et al). 2002;143:1017-26

Zehender M (see Brunner et al). 2002;143:1012-6

Zeni P (see Cicoira et al). 2002;143:1107-11

Zhao N (see Hillis et al). 2002;143:235-41

Zhao QM (see Sabatier et al). 2002;143:1027-32

Ziada KM (see Jeremias et al). 2002;143:1040-5

Zidar JP (see Berger et al). 2002;143:841-6

Ziegler M (see McNairy et al). 2002;143:406-11

Zipfel M (see Brunner et al). 2002;143:1012-6

# Subject index\*

## A

### Abciximab

Abciximab improves 6-month clinical outcome after rescue coronary angioplasty (Petronio et al). 2002;143:334-41

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CA-CHET) (Lincoff et al). 2002;143:847-53

Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists (Mazur et al). 2002; 143:594-601

Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects (Freedman et al). 2002;143: 87-94

Reduced inhibition by abciximab in platelets with the P1<sup>A2</sup> polymorphism (Wheeler et al). 2002;143:76-82

The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy (Wheeler et al). 2002;143:602-11

### Acromegaly

Treatment of acromegaly improves myocardial abnormalities (Vianna et al). 2002;143:873-6

### Acute coronary syndromes; see Angina, unstable; Myocardial infarction

### Adhesion molecules; see Cell adhesion molecules

### Adrenergic beta-antagonists

Beta blockers normalize QT hysteresis in long QT syndrome (Krahn et al). 2002;143:528-34

### AFFIRM Study

Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study (AFFIRM Investigators). 2002;143:991-1001

### African Americans; see Ethnic groups

### Aged

Cardiogenic shock complicating acute myocardial infarction in elderly patients: does admission to a tertiary center improve survival? (Berger et al). 2002;143:768-76

Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry) (Pulignano et al). 2002;143:45-55

Coronary stent implantation in patients older than 75 years of age: clinical profile and initial and long-term (3 years) outcome (Muñoz et al). 2002;143:620-6

Determinants of disability in older coronary patients (Ades et al). 2002;143:151-6

Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial (Minai et al). 2002;143:497-505

Should reperfusion strategies in myocardial infarction be modified for the very elderly? (Kroll and Ohman). 2002;143: 373-6 (Editorial)

Spectrum of heart failure in older patients: results from the National Heart Failure Project (Havranek et al). 2002;143: 412-17

### Albuminuria

Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with

\*January, pp. 1-186; February, pp. 187-372; March, pp. 373-558; April, pp. 559-744; May, pp. 745-930; June, pp. 931-1142.

electrocardiographic left ventricular hypertrophy: the LIFE study (Wachtell et al). 2002;143:319-26

### American Heart Association

Highlights from the American Heart Association Annual Scientific Sessions 2001: November 11 to 14, 2001 (Kandzari et al). 2002;143:217-28 (Meetings)

### Angina, unstable

Typical symptoms are predictive of acute coronary syndromes in women (Milner et al). 2002;143:283-8

### Angina, unstable, drug therapy

Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial (Antman et al). 2002;143: 229-34

Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control (Massel and Cruickshank). 2002;143:748-52

Incidence of high-risk acute coronary syndromes and eligibility for glycoprotein IIb/IIIa inhibitors among patients admitted for possible myocardial ischemia (Kontos et al). 2002;143: 70-5

Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes (Becker et al). 2002;143:753-9

Routine statin treatment after acute coronary syndromes? (Acedo et al). 2002;143:940-2 (Editorial)

The SYNERGY trial: study design and rationale (SYNERGY Executive Committee). 2002;143:952-60 (Trial design)

### Angina, unstable, therapy

Could direct stenting reduce no-reflow in acute coronary syndromes? A randomized pilot study (Sabatier et al). 2002;143: 1027-32

Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes (Cohen et al). 2002;143:63-9

Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment (Bahir et al). 2002; 143:205-16 (Curriculum cardiol.)

To cath or not to cath? That used to be the question (Cannon). 2002;143:377-80 (Editorial)

### Angiography

Electron beam tomography and angiography: sex differences (Budoff et al). 2002;143:877-82

Is there a benefit to early angiography in patients with ST-segment depression myocardial infarction? An observational study (Shavelle et al). 2002;143:488-96

Systemic platelet effects of contrast media: implications for cardiology research and clinical practice (Dalby et al). 2002; 143:e1

### Angioplasty

Relationship between coronary angioplasty laboratory volume and outcomes after hospital discharge (Kimmel et al). 2002; 143:833-40

### Angioplasty, transluminal, percutaneous coronary

Abciximab improves 6-month clinical outcome after rescue coronary angioplasty (Petronio et al). 2002;143:334-41

The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2) (Tamat et al). 2002;143:506-13

Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial (Minai et al). 2002;143:497-505

Natural history of small and medium-sized side branches after coronary stent implantation (Poerner et al). 2002;143:627-35

Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis Italian Study (ESPRIT) (Maresta et al). 2002; 143:e5

Six-month outcomes of percutaneous transluminal coronary angioplasty in hypertensive patients: results from the ROSETTA registry (Tsang et al). 2002;143:124-9

**Angiotensinogen**  
Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study (Tang et al). 2002;143:854-60

**Anti-inflammatory agents, non-steroidal**  
Aspirin: redundant in users of nonaspirin, nonsteroidal antiinflammatory agents? (Ray and Murray). 2002;143:381-2 (Editorial)  
Nonsteroidal antiinflammatory drugs after acute myocardial infarction (Ko et al). 2002;143:475-81

**Antibiotics**  
Antibiotics against *Clostridium pneumoniae* and prognosis after acute myocardial infarction (Pilote et al). 2002;143:294-300

**Antilipemic agents**  
Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy (Wink et al). 2002;143:514-18

Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent (Gouni-Berthold and Berthold). 2002;143:356-65

Routine statin treatment after acute coronary syndromes? (Avedo et al). 2002;143:940-2 (Editorial)

**Antithrombins, therapeutic; see Fibrinolytic agents**

**Anxiety**  
Association of anxiety with reduced baroreflex cardiac control in patients after acute myocardial infarction (Watkins et al). 2002;143:460-6

**Aorta, abdominal**  
Hepatocyte growth factor as a potential predictor of the presence of atherosclerotic aorto-iliac artery disease (Tateishi et al). 2002;143:272-6

**Arteriosclerosis**  
Determination of in vivo velocity and endothelial shear stress patterns with phasic flow in human coronary arteries: a methodology to predict progression of coronary atherosclerosis (Feldman et al). 2002;143:931-9

Hepatocyte growth factor as a potential predictor of the presence of atherosclerotic aorto-iliac artery disease (Tateishi et al). 2002;143:272-6

Inverse association between carotid intima-media thickness and the antioxidant lycopene in atherosclerosis (Gianetti et al). 2002;143:467-74

Prevalence of premature ventricular contractions in a population of African American and white men and women: the Atherosclerosis Risk in Communities (ARIC) Study (Simpson et al). 2002;143:535-40

**Aspirin**  
Aspirin: redundant in users of nonaspirin, nonsteroidal antiinflammatory agents? (Ray and Murray). 2002;143:381-2 (Editorial)  
Nonsteroidal antiinflammatory drugs after acute myocardial infarction (Ko et al). 2002;143:475-81

**Atrial fibrillation**  
Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study (AFFIRM Investigators). 2002;143:991-1001

Clinical and electrophysiologic effects of calcium channel blockers in patients receiving ibutilide (Wood et al). 2002;143:176-80

Effect of shock polarity on the efficacy of transthoracic atrial defibrillation (Rashba et al). 2002;143:541-5

Left ventricular function in atrial fibrillation during overdrive pacing (Vankawala et al). 2002;143:827-32

Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation (Dorian et al). 2002;143:984-90

Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective (Goldberg et al). 2002;143:519-27

The relative importance of left atrial function versus dimension in predicting atrial fibrillation after coronary artery bypass graft surgery (Nakai et al). 2002;143:181-6

**Atrial function, left**  
The relative importance of left atrial function versus dimension in predicting atrial fibrillation after coronary artery bypass graft surgery (Nakai et al). 2002;143:181-6

**Autonomic nervous system**  
Correlates of the shift in heart rate variability with an active postural change in a healthy population sample: the Atherosclerosis Risk in Communities study (Carnethon et al). 2002;143:808-13

Effects of cardiac rehabilitation and exercise training on autonomic regulation in patients with coronary artery disease (Lucini et al). 2002;143:977-83

Effects of sildenafil citrate (Viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure (Piccirillo et al). 2002;143:703-10

**Azimilide**  
Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response (Page et al). 2002;143:643-9

**B**

**B-natriuretic peptide; see Natriuretic peptide, brain**

**Baroreflex**  
Association of anxiety with reduced baroreflex cardiac control in patients after acute myocardial infarction (Watkins et al). 2002;143:460-6

A noninvasive measure of baroreflex sensitivity without blood pressure measurement (Davies et al). 2002;143:441-7

**Beta blockers; see Adrenergic beta-antagonists**

**Bisoprolol**  
Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies—CIBIS and CIBIS II (Leizorovicz et al). 2002;143:301-7

Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging (Dubach et al). 2002;143:676-83

**Bivalirudin**  
Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial (Antman et al). 2002;143:229-34

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CA-CIET) (Lincoff et al). 2002;143:847-53

Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin (White). 2002;143:189-92 (Editorial)

Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide (Kleiman et al). 2002;143:585-93

**Blacks; see Ethnic groups**

**Bleeding; see Hemorrhage**

**Blood coagulation**  
Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure (De Lorenzo et al). 2002;143:e3

**Blood flow velocity; see Hemodynamics**

**Blood platelets**  
Adhesion molecules, platelet activation, and cardiovascular risk (Gurbel and Serebruany). 2002;143:196-8 (Editorial)  
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein

IIb/IIIa receptor-directed platelet inhibition (Li et al). 2002; 143:725-32

Reduced inhibition by abciximab in platelets with the P1<sup>A2</sup> polymorphism (Wheeler et al). 2002;143:76-82

Systemic platelet effects of contrast media: implications for cardiology research and clinical practice (Dalby et al). 2002; 143:e1

**Blood pressure**

Acute blood pressure response to trandolapril and captopril in patients with left ventricular dysfunction after acute myocardial infarction (Weber et al). 2002;143:513-18

Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease (McCubbin et al). 2002;143:711-17

Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism (Dernellis and Panaretou). 2002;143:718-24

A noninvasive measure of baroreflex sensitivity without blood pressure measurement (Davies et al). 2002;143:441-7

**Brachial artery**

Effect of cigar smoking on endothelium-dependent brachial artery dilation in healthy young adults (Santo-Tomas et al). 2002;143:83-6

Large brachial artery diameter is associated with angiographic coronary artery disease in women (Holubkov et al). 2002; 143:802-7

**Bundle-branch block**

Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian Network on Congestive Heart Failure (Baldasseroni et al). 2002;143: 398-405

**C**

**CABG; see Coronary artery bypass**

**Calcium**

Coronary calcium and cardiovascular event risk: evaluation by age-and sex-specific quartiles (Wong et al). 2002;143:456-9

Coronary calcium scanning adds incremental value to patients with positive stress tests (LaMont et al). 2002;143:861-7

**Calcium channel blockers**

Clinical and electrophysiologic effects of calcium channel blockers in patients receiving ibutilide (Wood et al). 2002; 143:176-80

**Canadian Trial of Atrial Fibrillation**

Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation (Dorian et al). 2002;143:984-90

**Captopril**

Acute blood pressure response to trandolapril and captopril in patients with left ventricular dysfunction after acute myocardial infarction (Weber et al). 2002;143:313-18

**Cardiac resynchronization therapy**

Acute effects of cardiac resynchronization therapy on left ventricular Doppler indices in patients with congestive heart failure (Breithardt et al). 2002;143:34-44

**Cardiogenic shock; see Shock, cardiogenic**

**Cardiology**

An interventional cardiologist: a cardiologist who intervenes (Brush). 2002;143:943-4 (Editorial)

Recertification: mandatory or voluntary? Teaching old docs new tricks (Skorton and Mulhern). 2002;143:945 (Editorial)

Recertification: nobody asked me! (Klodos). 2002;143:946-7 (Editorial)

**Cardiomyopathy, congestive**

Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy (Cicero et al). 2002;143:1107-11

Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates (CWarraich et al). 2002;143:1076-84

Losartan treatment and left ventricular filling during volume loading in patients with dilated cardiomyopathy (Spinelli et al). 2002;143:433-40

No variants in the cardiac actin gene in Finnish patients with dilated or hypertrophic cardiomyopathy (Kärkkäinen et al). 2002;143:e6

Treatment of acromegaly improves myocardial abnormalities (Vianna et al). 2002;143:873-6

**Cardiomyopathy, hypertrophic**

Chronologic electrocardiographic changes in patients with hypertrophic cardiomyopathy associated with cardiac troponin I mutation (Shimizu et al). 2002;143:289-93

No variants in the cardiac actin gene in Finnish patients with dilated or hypertrophic cardiomyopathy (Kärkkäinen et al). 2002;143:e6

Septal wall thinning and systolic dysfunction in patients with hypertrophic cardiomyopathy caused by a cardiac troponin I gene mutation (Shimizu et al). 2002;143:690-5

**Cardioversion; see Electric countershock**

**Carotid arteries**

Inverse association between carotid intima-media thickness and the antioxidant lycopene in atherosclerosis (Gianetti et al). 2002;143:467-74

**Carvedilol**

Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters (Läer et al). 2002;143:916-22

**Catheterization**

To cath or not to cath? That used to be the question (Cannon). 2002;143:377-80 (Editorial)

**Caucasians; see Ethnic groups**

**Cell adhesion molecules**

Adhesion molecules, platelet activation, and cardiovascular risk (Gurbel and Serebrany). 2002;143:196-8 (Editorial)

Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia (Hillis et al). 2002;143:235-41

**Certification**

Recertification: mandatory or voluntary? Teaching old docs new tricks (Skorton and Mulhern). 2002;143:945 (Editorial)

Recertification: nobody asked me! (Klodos). 2002;143:946-7 (Editorial)

**Child**

Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters (Läer et al). 2002;143:916-22

Prophylactic Intravenous Use of Miramune After Cardiac Operation in Pediatrics (PRIMACORP) study (Hoffman et al). 2002;143:15-21 (Trial design)

Use of an implantable loop recorder in the evaluation of children with congenital heart disease (Sanatani et al). 2002; 143:366-72

**Chlamydophila pneumoniae**

Antibiotics against *Chlamydia pneumoniae* and prognosis after acute myocardial infarction (Pilote et al). 2002;143:294-300

**CIBIS and CIBIS II**

Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies—CIBIS and CIBIS II (Leizorovicz et al). 2002;143:301-7

**Clinical trials**

Are we asking too much of our trials? (Skali et al). 2002;143:1-3 (Editorial)

Choice of clinical outcomes in randomized trials of heart failure therapies: disease-specific or overall outcomes? (Yusuf and Negassa). 2002;143:22-8

Does enrollment in a randomized clinical trial lead to a higher cost of routine care? (Weiss et al). 2002;143:140-4

Making positive out of negative trials (Kandzari and Goldschmidt-Clermont). 2002;143:950-1 (Editorial)

Publication policy, informed consent, and the randomized clinical trial (Califf). 2002;143:187-8 (Editorial)

**Clinical trials data monitoring committees**

Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial (Mahaffey et al). 2002;143:242-8

**Clopidogrel**

Effect of 300-and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation (Seycraft et al). 2002;143:118-23

**Coagulation, blood; see Blood coagulation**

**Computed tomography; see Tomography, x-ray computed**

**Congenital heart defects; see Heart defects, congenital**

**Congestive heart failure; see Cardiomyopathy, congestive; Heart failure, congestive**

**Contrast media**

Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy (Tumlin et al). 2002;143:894-903

Systemic platelet effects of contrast media: implications for cardiology research and clinical practice (Dalby et al). 2002; 143:e1

Usefulness of an echo-contrast agent for assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery with transthoracic Doppler scan echocardiography (Okayama et al). 2002;143: 668-75

**Coronary artery bypass**

The relative importance of left atrial function versus dimension in predicting atrial fibrillation after coronary artery bypass graft surgery (Nakai et al). 2002;143:181-6

Variability in cost of coronary bypass surgery in New York State: potential for cost savings (Cowper et al). 2002;143:130-9

**Coronary disease**

CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction (Koch et al). 2002;143:971-6

Determinants of disability in older coronary patients (Ades et al). 2002;143:151-6

**Coronary disease, diagnosis**

Comparison of treadmill scores with physician estimates of diagnosis and prognosis in patients with coronary artery disease (Lipinski et al). 2002;143:650-8

Electron beam tomography and angiography: sex differences (Budoff et al). 2002;143:877-82

Large brachial artery diameter is associated with angiographic coronary artery disease in women (Holubkov et al). 2002; 143:802-7

Slow upslowing ST-segment depression during exercise: does it really signify a positive stress test? (Desai et al). 2002;143: 482-7

**Coronary disease, epidemiology**

Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease (McCubbin et al). 2002;143:711-17

Coronary calcium and cardiovascular event risk: evaluation by age-and sex-specific quartiles (Wong et al). 2002;143:456-9

Fibrinogen: associations with cardiovascular events in an outpatient clinic (Acevedo et al). 2002;143:277-82

**Coronary disease, prognosis**

The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy (Diderholm et al). 2002;143:760-7

Prognostic value of a negative stress echocardiographic study in diabetic patients (Kamlesh et al). 2002;143:163-8

**Coronary disease, therapy**

Benefits of an "angina clinic" for patients with coronary artery disease: a demonstration of health status measures as markers of health care quality (Spertus et al). 2002;143:145-50

Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease (Thompson et al). 2002; 143:249-56

Effect of surgical revascularization in patients with coronary artery disease and ventricular tachycardia or fibrillation in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry (Cook et al). 2002;143:821-6

Effects of cardiac rehabilitation and exercise training on autonomic regulation in patients with coronary artery disease (Lucini et al). 2002;143:977-83

Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease (Church et al). 2002;143:349-55

Staged versus one-step approach for multivessel percutaneous coronary interventions (Nikolsky et al). 2002;143:1017-26

**Coronary restenosis**

Centered versus noncentered source for intracoronary artery radiation therapy: a model based on the Scripps Trial (Arbab-Zadeh et al). 2002;143:342-8

Impact of geographic miss on adjacent coronary artery segments in diffuse in-stent restenosis with -radiation therapy: angiographic and intravascular ultrasound analysis (Hong et al). 2002;143:327-33

The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2) (Tamai et al). 2002;143:506-13

Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT) (Maresta et al). 2002; 143:e5

**Coronary vessels**

Centered versus noncentered source for intracoronary artery radiation therapy: a model based on the Scripps Trial (Arbab-Zadeh et al). 2002;143:342-8

Determination of in vivo velocity and endothelial shear stress patterns with phasic flow in human coronary arteries: a methodology to predict progression of coronary atherosclerosis (Feldman et al). 2002;143:931-9

Natural history of small and medium-sized side branches after coronary stent implantation (Poerner et al). 2002;143:627-35

Two vessels or not two vessels? That is the question (Kahn and O'Neill). 2002;143:948-9 (Editorial)

Usefulness of an echo-contrast agent for assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery with transthoracic Doppler scan echocardiography (Okayama et al). 2002;143: 668-75

**Corrections**

Primary and subsequent coronary risk appraisal: new results from the Framingham Study (D'Agostino et al) (2000;139: 272-81). 2002;143:21

**Costs and cost analysis**

Cost and cost-effectiveness studies in heart failure research (Weintraub et al). 2002;143:565-76 (Prog. cardiol.)

Does enrollment in a randomized clinical trial lead to a higher cost of routine care? (Weiss et al). 2002;143:140-4

Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (Eplerenone's neuroHormonal Efficacy and Survival Study) (Spertus et al). 2002;143:636-42

Variability in cost of coronary bypass surgery in New York State: potential for cost savings (Cowper et al). 2002;143:130-9

Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial (Eisenstein et al). 2002;143:1112-7

**Crataegus**

Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure (Tauchert). 2002; 143:910-15

### Creatine kinase

Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction (Jeremias et al). 2002;143:1040-5  
Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy (Gibson et al). 2002;143:106-10

### Creatinine

Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study (Wachtell et al). 2002;143:319-26

### Critical pathways

Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program (National Heart Attack Alert Program Coordinating Committee). 2002;143:777-89

## D

### Deceleration time of early filling

Deceleration time of early filling in patients with left ventricular systolic dysfunction: functional and prognostic independent value (Morales et al). 2002;143:1101-6

### Defibrillation; *see* Electric countershock

### Defibrillators, implantable

The Low Energy Safety Study (LESS): rationale, design, patient characteristics, and device utilization (Mann et al). 2002;143:199-204 (Trial design)

### Diabetes mellitus

Prognostic value of a negative stress echocardiographic study in diabetic patients (Kamlesh et al). 2002;143:163-8

### Disability evaluation

Determinants of disability in older coronary patients (Ades et al). 2002;143:151-6

### Dobutamine

Assessment of cardiac viability by thallium 201 redistribution and dobutamine echocardiography (Zamorano et al). 2002;143:157-62

Early systolic mitral annular motion velocities responses to dobutamine infusion predict myocardial viability in patients with previous myocardial infarction (Matsuoka et al). 2002;143:552-8

Influence of left ventricular size and hemodynamics on the systolic longitudinal myocardial Doppler velocity response to stress (Cain et al). 2002;143:169-75

Magnetic resonance tagging and echocardiographic response to dobutamine and functional improvement after reperfused myocardial infarction (Kramer et al). 2002;143:1046-51

### Dopamine

The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure (Ferreira et al). 2002;143:391-7

### Doppler echocardiography; *see* Echocardiography, Doppler

### Ductus arteriosus, patent

Early reopening and recanalization after successful coil occlusion of the patent ductus arteriosus (Turner et al). 2002;143:889-93

### DUETT vascular hemostasis device

Assessment of the safety and efficacy of the DUETT vascular hemostasis device: final results of the Safe and Effective Vascular Hemostasis (SEAL) trial (SEAL Trial Study Team). 2002;143:612-19

## E

### Echocardiography

Comparison of 2-dimensional echocardiography and myocardial

perfusion imaging for diagnosing myocardial infarction in emergency department patients (Kontos et al). 2002;143:659-67

The heart in neurofibromatosis type 1: an echocardiographic study (Tedesco et al). 2002;143:883-8

Magnetic resonance tagging and echocardiographic response to dobutamine and functional improvement after reperfused myocardial infarction (Kramer et al). 2002;143:1046-51

### Echocardiography, Doppler

Acute effects of cardiac resynchronization therapy on left ventricular Doppler indices in patients with congestive heart failure (Breithardt et al). 2002;143:34-44

Usefulness of an echo-contrast agent for assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery with transthoracic Doppler scan echocardiography (Okayama et al). 2002;143:668-75

### Echocardiography, stress

Assessment of cardiac viability by thallium 201 redistribution and dobutamine echocardiography (Zamorano et al). 2002;143:157-62

Early systolic mitral annular motion velocities responses to dobutamine infusion predict myocardial viability in patients with previous myocardial infarction (Matsuoka et al). 2002;143:552-8

Influence of left ventricular size and hemodynamics on the systolic longitudinal myocardial Doppler velocity response to stress (Cain et al). 2002;143:169-75

Prognostic value of a negative stress echocardiographic study in diabetic patients (Kamlesh et al). 2002;143:163-8

### Editorials

Adhesion molecules, platelet activation, and cardiovascular risk (Gurbel and Serebruany). 2002;143:196-8

Are we asking too much of our trials? (Skali et al). 2002;143:1-3

Aspirin: redundant in users of nonaspirin, nonsteroidal antiinflammatory agents? (Ray and Murray). 2002;143:381-2

Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin (White). 2002;143:189-92

An interventional cardiologist: a cardiologist who intervenes (Brush). 2002;143:943-4

Is more better? (Nash and Jollis). 2002;143:745-7

Making positive out of negative trials (Kandzari and Goldschmidt-Clermont). 2002;143:950-1

Publication policy, informed consent, and the randomized clinical trial (Califf). 2002;143:187-8

Recertification: mandatory or voluntary? Teaching old docs new tricks (Skorton and Mulhern). 2002;143:945

Recertification: nobody asked me! (Kladas). 2002;143:946-7

Routine statin treatment after acute coronary syndromes? (Avedo et al). 2002;143:940-2

Should reperfusion strategies in myocardial infarction be modified for the very elderly? (Kroll and Obman). 2002;143:373-6

Stored iron and myocardial perfusion deficits (Sullivan). 2002;143:193-5

To cath or not to cath? That used to be the question (Cannon). 2002;143:377-80

Two vessels or not two vessels? That is the question (Kahn and O'Neill). 2002;143:948-9

When young hearts are broken: profiles of premature myocardial infarction (Pasricha and Batchelor). 2002;143:4-6

### Efegatran

Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: the Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial (PRIME Investigators). 2002;143:95-105

### Eisenmenger complex

Poor prognosis and related factors in adults with Eisenmenger syndrome (Oya et al). 2002;143:739-44

**Elderly; see Aged****Electric countershock**

Effect of shock polarity on the efficacy of transthoracic atrial defibrillation (Rashba et al). 2002;143:541-5

The Low Energy Safety Study (LESS): rationale, design, patient characteristics, and device utilization (Mann et al). 2002;143:199-204 (Trial design)

**Electrocardiography**

Chronologic electrocardiographic changes in patients with hypertrophic cardiomyopathy associated with cardiac troponin I mutation (Shimizu et al). 2002;143:289-93

The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy (Diderholm et al). 2002;143:760-7

QRS duration and mortality in patients with congestive heart failure (Iuliano et al). 2002;143:1085-91

Slow upsloping ST-segment depression during exercise: does it really signify a positive stress test? (Desai et al). 2002;143:482-7

Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction (Kurisu et al). 2002;143:448-55

**Endothelium, vascular**

Determination of in vivo velocity and endothelial shear stress patterns with phasic flow in human coronary arteries: a methodology to predict progression of coronary atherosclerosis (Feldman et al). 2002;143:931-9

Effect of cigar smoking on endothelium-dependent brachial artery dilation in healthy young adults (Santo-Tomas et al). 2002;143:83-6

Vascular dysfunction and heart failure: epiphénoménon or etiologic agent? (Fang and Marwick). 2002;143:383-90 (Curriculum cardioli)

**Endpoint determination**

Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial (Mahaffey et al). 2002;143:242-8

**Enoxaparin**

Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control (Massel and Cruickshank). 2002;143:748-52

Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes (Becker et al). 2002;143:753-9

The SYNERGY trial: study design and rationale (SYNERGY Executive Committee). 2002;143:952-60 (Trial design)

**Eplerenone**

Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (Eplerenone's neuroHormonal Efficacy and SURvival Study) (Speratus et al). 2002;143:636-42

**Eptifibatide**

Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide (Kleiman et al). 2002;143:585-93

**Ethnic groups**

Differences between African Americans and whites in the outcome of heart failure: evidence for a greater functional decline in African Americans (Vaccarino et al). 2002;143:1058-67

Prevalence of premature ventricular contractions in a population of African American and white men and women: the Atherosclerosis Risk in Communities (ARIC) Study (Simpson et al). 2002;143:535-40

**Exercise**

Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging (Dubach et al). 2002;143:676-83

Effects of cardiac rehabilitation and exercise training on autonomic regulation in patients with coronary artery disease (Lucini et al). 2002;143:977-83

Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure (Tauchert). 2002;143:910-15

Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease (Church et al). 2002;143:349-55

Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide (McNairy et al). 2002;143:406-11

**Exercise test**

Comparison of treadmill scores with physician estimates of diagnosis and prognosis in patients with coronary artery disease (Lipinski et al). 2002;143:650-8

Comparison of ventilatory expired gas parameters used to predict hospitalization in patients with heart failure (Arena and Humphrey). 2002;143:427-32

Coronary calcium scanning adds incremental value to patients with positive stress tests (LaMont et al). 2002;143:861-7

Do transmyocardial and percutaneous laser revascularization induce silent ischemia? An assessment by exercise testing (Myers et al). 2002;143:1052-7

Prognostic impact of workload in patients with congestive heart failure (Huelsmann et al). 2002;143:308-12

Slow upsloping ST-segment depression during exercise: does it really signify a positive stress test? (Desai et al). 2002;143:482-7

Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity (Corra et al). 2002;143:418-26

**F****Factor Xa**

Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes (Becker et al). 2002;143:753-9

**Fatty acids, omega-3**

Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Espart for Prevention of Restenosis ITalian Study (ESPRIT) (Mareste et al). 2002;143:e5

**Fenoldopam**

Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy (Tumlin et al). 2002;143:894-903

**Fibrinogen**

Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition (Li et al). 2002;143:725-32

Fibrinogen: associations with cardiovascular events in an outpatient clinic (Acevedo et al). 2002;143:277-82

**Fibrinolytic agents**

Identification of patients at high risk for death and cardiac ischemic events after hospital discharge (Sabatine et al). 2002;143:966-70

**Framingham Offspring Study**

Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study (Murabito et al). 2002;143:961-5

## G

**Genetic mutation; see Mutation**  
**Genetic polymorphism; see Polymorphism (genetics)**  
**Glycoprotein IIb/IIIa complex inhibitors; see Platelet aggregation inhibitors**

## H

**HDLs; see Lipoproteins, HDL**

**Health status indicators**

Benefits of an "angina clinic" for patients with coronary artery disease: a demonstration of health status measures as markers of health care quality (Spertus et al). 2002;143:145-50

**Heart defects, congenital**

Early reopening and recanalization after successful coil occlusion of the patent ductus arteriosus (Turner et al). 2002;143:889-93

The heart in neurofibromatosis type 1: an echocardiographic study (Tedesco et al). 2002;143:883-8

Intrauterine diagnosis of heterotaxy syndrome (Lin et al). 2002;143:1002-8

Poor prognosis and related factors in adults with Eisenmenger syndrome (Oya et al). 2002;143:739-44

Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics (PRIMACORP) study (Hoffman et al). 2002;143:15-21 (Trial design)

Use of an implantable loop recorder in the evaluation of children with congenital heart disease (Sanatani et al). 2002;143:366-72

**Heart failure, congestive**

Choice of clinical outcomes in randomized trials of heart failure therapies: disease-specific or overall outcomes? (Yusuf and Negassa). 2002;143:22-8

Cost and cost-effectiveness studies in heart failure research (Weintraub et al). 2002;143:565-76 (Prog. cardiol.)

Effects of sildenafil citrate (Viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure (Piccirillo et al). 2002;143:703-10

Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide (McNairy et al). 2002;143:406-11

**Heart failure, congestive, drug therapy**

Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies—CIBIS and CIBIS II (Leizorovicz et al). 2002;143:301-7

Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters (Läer et al). 2002;143:916-22

Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging (Dubach et al). 2002;143:676-83

Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure (Tauchert). 2002;143:910-15

Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure (De Lorenzo et al). 2002;143:e2

Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial (Eisenstein et al). 2002;143:1112-7

**Heart failure, congestive, epidemiology**

Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry) (Puglisi et al). 2002;143:45-55

Differences between African Americans and whites in the out-

come of heart failure: evidence for a greater functional decline in African Americans (Vaccarino et al). 2002;143:1058-67

Spectrum of heart failure in older patients: results from the National Heart Failure Project (Havranek et al). 2002;143:412-17

**Heart failure, congestive, pathophysiology**

Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? (Gurbel et al). 2002;143:1068-75

The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure (Ferreira et al). 2002;143:391-7

Vascular dysfunction and heart failure: epiphenomenon or etiologic agent? (Fang and Marwick). 2002;143:383-90 (Curriculum cardiol.)

**Heart failure, congestive, prognosis**

Comparison of ventilatory expired gas parameters used to predict hospitalization in patients with heart failure (Arena and Humphrey). 2002;143:427-32

Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian Network on Congestive Heart Failure (Baldasseroni et al). 2002;143:398-405

Prognostic impact of workload in patients with congestive heart failure (Huelsmann et al). 2002;143:308-12

QRS duration and mortality in patients with congestive heart failure (Juliano et al). 2002;143:1085-91

Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity (Corrà et al). 2002;143:418-26

**Heart failure, congestive, therapy**

Acute effects of cardiac resynchronization therapy on left ventricular Doppler indices in patients with congestive heart failure (Breithardt et al). 2002;143:34-44

Long-term outcome and the use of revascularization in patients with heart failure, suspected ischemic heart disease, and large reversible myocardial perfusion defects (Miller et al). 2002;143:904-9

Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction (Jeejeebhoy et al). 2002;143:1085-91

Potential contributing factors to noncompliance with dietary sodium restriction in patients with heart failure (Neily et al). 2002;143:29-33

**Heart rate**

Correlates of the shift in heart rate variability with an active postural change in a healthy population sample: the Atherosclerosis Risk In Communities study (Carnethon et al). 2002;143:808-13

A noninvasive measure of baroreflex sensitivity without blood pressure measurement (Davies et al). 2002;143:441-7

Transmyocardial laser revascularization and left ventricular reduction surgery affect ventricular arrhythmias and heart rate variability (Brunner et al). 2002;143:1012-6

**Heart valve diseases**

Spontaneous resolution of obstructive valvular tumors in infants (Guntheroth et al). 2002;143:868-72

**Hemodynamics**

Determination of in vivo velocity and endothelial shear stress patterns with phasic flow in human coronary arteries: a methodology to predict progression of coronary atherosclerosis (Feldman et al). 2002;143:931-9

Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction (French et al). 2002;143:265-71

Influence of left ventricular size and hemodynamics on the systolic longitudinal myocardial Doppler velocity response to stress (Cain et al). 2002;143:169-75

**Usefulness of an echo-contrast agent for assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery with transthoracic Doppler scan echocardiography (Okayama et al). 2002;143:668-75**

**Hemorheology**  
Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease (Church et al). 2002;143:349-55

**Hemorrhage**  
Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin (White). 2002;143:189-92 (Editorial)

**Hemostasis**  
Assessment of the safety and efficacy of the DUETT vascular hemostasis device: final results of the Safe and Effective Vascular Hemostasis (SEAL) trial (SEAL Trial Study Team). 2002;143:612-19

**Heparin**  
Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial (Antman et al). 2002;143:229-34

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CA-CIET) (Lincoff et al). 2002;143:847-53

Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure (De Lorenzo et al). 2002;143:e3

Multicenter, dose-ranging study of efgatran sulfate versus heparin with thrombolysis for acute myocardial infarction: the Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial (PRIME Investigators). 2002;143:95-105

**Hepatocyte growth factor**  
Hepatocyte growth factor as a potential predictor of the presence of atherosclerotic aorto-iliac artery disease (Tateishi et al). 2002;143:272-6

**Heterotaxy syndrome**  
Intrauterine diagnosis of heterotaxy syndrome (Lin et al). 2002;143:1002-8

**Hormone replacement therapy**  
Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease (McCubbin et al). 2002;143:711-17

Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism (Dernellis and Panaretou). 2002;143:718-24

**Hypercholesterolemia**  
Impact of body iron status on myocardial perfusion, left ventricular function, and angiographic morphologic features in patients with hypercholesterolemia (Say et al). 2002;143:257-64

**Hypertension**  
Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism (Dernellis and Panaretou). 2002;143:718-24

Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy (Mohri et al). 2002;143:684-9

Myocardial function and geometry in hypertensive subjects with low levels of afterload (Aurigemma et al). 2002;143:546-51

Six-month outcomes of percutaneous transluminal coronary angioplasty in hypertensive patients: results from the ROSETTA registry (Tsang et al). 2002;143:124-9

Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study (Wachtell et al). 2002;143:319-26

**Hypertension, pulmonary**  
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension (Langleben et al). 2002;143:e4

**Hypertrophic, renovascular**  
Renal artery stenosis: a cardiovascular perspective (Vashist et al). 2002;143:559-64 (Curriculum cardiol.)

**Hypertrophic cardiomyopathy; see Cardiomyopathy, hypertrophic**

**Hypertrophy, left ventricular**  
Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study (Tang et al). 2002;143:854-60

Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations (Groenning et al). 2002;143:923-9

Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy (Mohri et al). 2002;143:684-9

Myocardial function and geometry in hypertensive subjects with low levels of afterload (Aurigemma et al). 2002;143:546-51

Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study (Wachtell et al). 2002;143:319-26

**Hypothyroidism**  
Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism (Dernellis and Panaretou). 2002;143:718-24

**I**

**Ibutilide**  
Clinical and electrophysiologic effects of calcium channel blockers in patients receiving ibutilide (Wood et al). 2002;143:176-80

**Immunoglobulin G**  
Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates (Warraich et al). 2002;143:1076-84

**Infant**  
Spontaneous resolution of obstructive valvular tumors in infants (Guntheroth et al). 2002;143:868-72

**Informed consent**  
Publication policy, informed consent, and the randomized clinical trial (Califf). 2002;143:187-8 (Editorial)

**Iron**  
Impact of body iron status on myocardial perfusion, left ventricular function, and angiographic morphologic features in patients with hypercholesterolemia (Say et al). 2002;143:257-64

Stored iron and myocardial perfusion deficits (Sullivan). 2002;143:193-5 (Editorial)

**K**

**Kidney failure, chronic**  
Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction (Jeremias et al). 2002;143:1040-5

**L**

**Laboratories, hospital**  
Relationship between coronary angioplasty laboratory volume and outcomes after hospital discharge (Kimmel et al). 2002;143:833-40

## Lasers

Do transmyocardial and percutaneous laser revascularization induce silent ischemia? An assessment by exercise testing (Myers et al). 2002;143:1052-7

Transmyocardial laser revascularization and left ventricular reduction surgery affect ventricular arrhythmias and heart rate variability (Brunner et al). 2002;143:1012-6

## Lip

Morphologic changes in the microcirculation induced by chronic smoking habit: a videocapillaroscopic study on the human labial mucosa (Lova et al). 2002;143:e2

## Lipid-lowering agents; *see* Antilipemic agents

## Lipids

Increased postprandial lipemia in patients with normolipemic peripheral arterial disease (Lupattelli et al). 2002;143:733-8

## Lipoproteins, HDL

Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy (Wink et al). 2002;143:514-18

## Long QT syndrome

Beta blockers normalize QT hysteresis in long QT syndrome (Krahn et al). 2002;143:528-34

Long QT syndrome: diagnosis and management (Khan). 2002;143:7-14 (Curriculum cardiol.)

## Loop recorders, implantable

Use of an implantable loop recorder in the evaluation of children with congenital heart disease (Sanatani et al). 2002;143:366-72

## Losartan

Losartan treatment and left ventricular filling during volume loading in patients with dilated cardiomyopathy (Spinelli et al). 2002;143:433-40

## Low Energy Safety Study (LESS)

The Low Energy Safety Study (LESS): rationale, design, patient characteristics, and device utilization (Mann et al). 2002;143:199-204 (Trial design)

## Lycopene

Inverse association between carotid intima-media thickness and the antioxidant lycopene in atherosclerosis (Gianetti et al). 2002;143:467-74

## M

## Magnetic resonance imaging

Magnetic resonance tagging and echocardiographic response to dobutamine and functional improvement after reperfused myocardial infarction (Kramer et al). 2002;143:1046-51

## Microcirculation

Morphologic changes in the microcirculation induced by chronic smoking habit: a videocapillaroscopic study on the human labial mucosa (Lova et al). 2002;143:e2

## Milrinone

Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics (PRIMACORP) study (Hoffman et al). 2002;143:15-21 (Trial design)

## Mitral valve

Early systolic mitral annular motion velocities responses to dobutamine infusion predict myocardial viability in patients with previous myocardial infarction (Matsuoka et al). 2002;143:552-8

## Mortality

Cardiac troponin T levels are associated with poor short-and long-term prognosis in patients with acute cardiogenic pulmonary edema (Perna et al). 2002;143:814-20

Identification of patients at high risk for death and cardiac ischemic events after hospital discharge (Sabatine et al). 2002;143:966-70

Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian Network

on Congestive Heart Failure (Baldasseroni et al). 2002;143:398-405

QRS duration and mortality in patients with congestive heart failure (Juliano et al). 2002;143:1085-91

Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective (Goldberg et al). 2002;143:519-27

## Mutation

Chronologic electrocardiographic changes in patients with hypertrophic cardiomyopathy associated with cardiac troponin I mutation (Shimizu et al). 2002;143:289-93

No variants in the cardiac actin gene in Finnish patients with dilated or hypertrophic cardiomyopathy (Kärkkäinen et al). 2002;143:e6

Septal wall thinning and systolic dysfunction in patients with hypertrophic cardiomyopathy caused by a cardiac troponin I gene mutation (Shimizu et al). 2002;143:690-5

## Myocardial infarction

Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial (Mahaffey et al). 2002;143:242-8

Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction (Kurisu et al). 2002;143:448-55

## Myocardial infarction, diagnosis

Comparison of 2-dimensional echocardiography and myocardial perfusion imaging for diagnosing myocardial infarction in emergency department patients (Kontos et al). 2002;143:659-67

Typical symptoms are predictive of acute coronary syndromes in women (Milner et al). 2002;143:283-8

## Myocardial infarction, drug therapy

Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial (Antman et al). 2002;143:229-34

Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control (Massel and Cruickshank). 2002;143:748-52

Incidence of high-risk acute coronary syndromes and eligibility for glycoprotein IIb/IIIa inhibitors among patients admitted for possible myocardial ischemia (Kontos et al). 2002;143:70-5

Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes (Becker et al). 2002;143:753-9  
Multicenter, dose-ranging study of eptifibatide sulfate versus heparin with thrombolysis for acute myocardial infarction: the Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial (PRIME Investigators). 2002;143:95-105

Nonsteroidal antiinflammatory drugs after acute myocardial infarction (Ko et al). 2002;143:475-81

Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment (Babit et al). 2002;143:205-16 (Curriculum cardiol.)

Routine statin treatment after acute coronary syndromes? (Acedo et al). 2002;143:940-2 (Editorial)

The SYNERGY trial: study design and rationale (SYNERGY Executive Committee). 2002;143:952-60 (Trial design)

## Myocardial infarction, epidemiology

Acute myocardial infarction in the young—the University of Michigan experience (Dougherty et al). 2002;143:56-62

Fibrinogen: associations with cardiovascular events in an outpatient clinic (Acedo et al). 2002;143:277-82

Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective (Goldberg et al). 2002;143:519-27

When young hearts are broken: profiles of premature myocar-

dial infarction (Pasricha and Batchelor). 2002;143:46 (Editorial)

**Myocardial infarction, pathophysiology**

Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction (Nakayama et al). 2002;143:797-801

Association of anxiety with reduced baroreflex cardiac control in patients after acute myocardial infarction (Watkins et al). 2002;143:460-6

CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction (Koch et al). 2002;143:971-6

Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide (Nilsson et al). 2002;143:696-702

**Myocardial infarction, prognosis**

Antibiotics against *Chlamydia pneumoniae* and prognosis after acute myocardial infarction (Pilote et al). 2002;143:294-300

Cardiogenic shock complicating acute myocardial infarction in elderly patients: does admission to a tertiary center improve survival? (Berger et al). 2002;143:768-76

Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction (Inoue et al). 2002;143:790-6

Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction (French et al). 2002;143:265-71

Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts (Shah et al). 2002;143:111-17

**Myocardial infarction, therapy**

Could direct stenting reduce no-reflow in acute coronary syndromes? A randomized pilot study (Sabatier et al). 2002;143:1027-32

Is there a benefit to early angiography in patients with ST-segment depression myocardial infarction? An observational study (Shavelle et al). 2002;143:488-96

Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial (Minai et al). 2002;143:497-505

Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes (Cohen et al). 2002;143:63-9

Should reperfusion strategies in myocardial infarction be modified for the very elderly? (Kroll and Ohman). 2002;143:373-6 (Editorial)

To cath or not to cath? That used to be the question (Cannon). 2002;143:377-80 (Editorial)

Use of the invasive management strategy for patients with non-Q-wave myocardial infarction: an observational database report from the Worcester Heart Attack Study (Dauerman et al). 2002;143:1033-9

**Myocardial ischemia**

Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease (Thompson et al). 2002;143:249-56

Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia (Hillis et al). 2002;143:235-41

Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy (Mohri et al). 2002;143:684-9

Identification of patients at high risk for death and cardiac ischemic events after hospital discharge (Sabatine et al). 2002;143:966-70

Long-term outcome and the use of revascularization in patients with heart failure, suspected ischemic heart disease, and large reversible myocardial perfusion defects (Miller et al). 2002;143:904-9

Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts (Shah et al). 2002;143:111-17

**Myocardial perfusion; see Perfusion**

**Myocardial perfusion imaging; see Radionuclide imaging**

**Myocardial reperfusion**

Magnetic resonance tagging and echocardiographic response to dobutamine and functional improvement after reperfused myocardial infarction (Kramer et al). 2002;143:1046-51

Should reperfusion strategies in myocardial infarction be modified for the very elderly? (Kroll and Ohman). 2002;143:373-6 (Editorial)

**Myocardial revascularization**

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CA-CHET) (Lincoff et al). 2002;143:847-53

Do transmyocardial and percutaneous laser revascularization induce silent ischemia? An assessment by exercise testing (Myers et al). 2002;143:1052-7

Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction (Inoue et al). 2002;143:790-6

Effect of surgical revascularization in patients with coronary artery disease and ventricular tachycardia or fibrillation in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry (Cook et al). 2002;143:821-6

Long-term outcome and the use of revascularization in patients with heart failure, suspected ischemic heart disease, and large reversible myocardial perfusion defects (Miller et al). 2002;143:904-9

Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction (Jeremias et al). 2002;143:1040-5

Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts (Shah et al). 2002;143:111-17

Staged versus one-step approach for multivessel percutaneous coronary interventions (Nikolsky et al). 2002;143:1017-26

Transmyocardial laser revascularization and left ventricular reduction surgery affect ventricular arrhythmias and heart rate variability (Brunner et al). 2002;143:1012-6

Two vessels or not two vessels? That is the question (Kahn and O'Neill). 2002;143:948-9 (Editorial)

**Myocardium**

Assessment of cardiac viability by thallium 201 redistribution and dobutamine echocardiography (Zamorano et al). 2002;143:157-62

Early systolic mitral annular motion velocities responses to dobutamine infusion predict myocardial viability in patients with previous myocardial infarction (Matsuoka et al). 2002;143:552-8

Myocardial function and geometry in hypertensive subjects with low levels of afterload (Aurigemma et al). 2002;143:546-51

**Myxoma**

Spontaneous resolution of obstructive valvular tumors in infants (Guntheroth et al). 2002;143:868-72

**N****National Heart Attack Alert Program**

Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program (National Heart Attack Alert Program Coordinating Committee). 2002;143:777-89

### National Heart Failure Project

Spectrum of heart failure in older patients: results from the National Heart Failure Project (Havranek et al). 2002;143:412-17

### Natriuretic peptide, brain

Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations (Groenning et al). 2002;143:923-9

Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction (Inoue et al). 2002;143:790-6

Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide (Nilsson et al). 2002;143:696-702

Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide (McNairy et al). 2002;143:406-11

### Neurofibromatoses

The heart in neurofibromatosis type 1: an echocardiographic study (Tedesco et al). 2002;143:883-8

### Neurotransmitters

The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure (Ferreira et al). 2002;143:391-7

### New York

Variability in cost of coronary bypass surgery in New York State: potential for cost savings (Cowper et al). 2002;143:130-9

### Niacin

Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy (Wink et al). 2002;143:514-18

### Nitric oxide

Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy (Mohri et al). 2002;143:684-9

### Noncompliance; see Treatment refusal

### NSAIDs; see Anti-inflammatory agents, non-steroidal

### Nutritional support

Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction (Jeejeebhoy et al). 2002;143:1092-100

## O

### Omega-3 fatty acids; see Fatty acids, omega-3

### Outcome assessment (health care)

Abciximab improves 6-month clinical outcome after rescue coronary angioplasty (Petrovion et al). 2002;143:334-41

Are we asking too much of our trials? (Skali et al). 2002;143:1-3 (Editorial)

Choice of clinical outcomes in randomized trials of heart failure therapies: disease-specific or overall outcomes? (Yusuf and Negassa). 2002;143:22-8

Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry) (Puglionesi et al). 2002;143:45-55

Coronary stent implantation in patients older than 75 years of age: clinical profile and initial and long-term (3 years) outcome (Muñoz et al). 2002;143:620-6

Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction (French et al). 2002;143:265-71

Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (Eplerenone's neuroHormonal Efficacy and SUrvival Study) (Spertus et al). 2002;143:636-42

Is more better? (Nash and Jollis). 2002;143:745-7 (Editorial)

Long-term outcome and the use of revascularization in patients with heart failure, suspected ischemic heart disease, and large reversible myocardial perfusion defects (Miller et al). 2002;143:904-9

Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial (Minai et al). 2002;143:497-505

Relationship between coronary angioplasty laboratory volume and outcomes after hospital discharge (Kimmel et al). 2002;143:833-40

Six-month outcomes of percutaneous transluminal coronary angioplasty in hypertensive patients: results from the ROSETTA registry (Tsang et al). 2002;143:124-9

## P

### P-selectin

Effect of 300-and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation (Seyfarth et al). 2002;143:118-23

Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia (Hillis et al). 2002;143:235-41

### Pacemaker, artificial

Left ventricular function in atrial fibrillation during overdrive pacing (Vankawala et al). 2002;143:827-32

Low settings of the ventricular pacing output in patients dependent on a pacemaker: are they really safe? (Schuchert et al). 2002;143:1009-11

### Patent ductus arteriosus; see Ductus arteriosus, patent

### Pediatric patient; see Child

### Percutaneous coronary intervention; see Myocardial revascularization

### Perfusion

Comparison of 2-dimensional echocardiography and myocardial perfusion imaging for diagnosing myocardial infarction in emergency department patients (Kontos et al). 2002;143:659-67

Impact of body iron status on myocardial perfusion, left ventricular function, and angiographic morphologic features in patients with hypercholesterolemia (Say et al). 2002;143:257-64

Relationship of creatine kinase-myocardial band release to Thrombolytic in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy (Gibson et al). 2002;143:106-10

Stored iron and myocardial perfusion deficits (Sullivan). 2002;143:193-5 (Editorial)

### Peripheral vascular diseases

Increased postprandial lipemia in patients with normolipemic peripheral arterial disease (Lupattelli et al). 2002;143:733-8

Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study (Murabito et al). 2002;143:961-5

### Platelet aggregation inhibitors

Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition (Li et al). 2002;143:725-32

Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists (Mazur et al). 2002;143:594-601

Incidence of high-risk acute coronary syndromes and eligibility for glycoprotein IIb/IIIa inhibitors among patients admitted for possible myocardial ischemia (Kontos et al). 2002;143:70-5

**Platelet function tests**

Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? (Gurbel et al). 2002;143:1068-75

The Ultregra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy (Wheeler et al). 2002;143:602-11

**Platelets; see Blood platelets****Policosanol**

Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent (Gouni-Berthold and Berthold). 2002;143:356-65

**Polymorphism (genetics)**

Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction (Nakayama et al). 2002;143:797-801

Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study (Tang et al). 2002;143:854-60

CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction (Koch et al). 2002;143:971-6

Making positive out of negative trials (Kandzari and Goldschmidt-Clermont). 2002;143:950-1 (Editorial)

Reduced inhibition by abciximab in platelets with the P1<sup>32</sup> polymorphism (Wheeler et al). 2002;143:76-82

**Postprandial period**

Increased postprandial lipemia in patients with normolipemic peripheral arterial disease (Lupattelli et al). 2002;143:733-8

**Posture**

Correlates of the shift in heart rate variability with an active postural change in a healthy population sample: the Atherosclerosis Risk In Communities study (Carmethon et al). 2002;143:808-13

**Prayer, intercessory; see Spiritual therapies****Premature ventricular contractions; see Ventricular premature complexes****Prenatal diagnosis**

Intrauterine diagnosis of heterotaxy syndrome (Lin et al). 2002;143:1002-8

**Prostacyclin synthase gene**

Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction (Nakayama et al). 2002;143:797-801

**PTCA; see Angioplasty, transluminal, percutaneous coronary****Publications**

Publication policy, informed consent, and the randomized clinical trial (Califf). 2002;143:187-8 (Editorial)

**Pulmonary edema**

Cardiac troponin T levels are associated with poor short-and long-term prognosis in patients with acute cardiogenic pulmonary edema (Perma et al). 2002;143:814-20

**Pulmonary hypertension; see Hypertension, pulmonary****Pulmonary ventilation**

Comparison of ventilatory expired gas parameters used to predict hospitalization in patients with heart failure (Arena and Humphrey). 2002;143:427-32

Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity (Corrà et al). 2002;143:418-26

**Q****QRS complex; see Electrocardiography****Quality of health care**

Benefits of an "angina clinic" for patients with coronary artery disease: a demonstration of health status measures as markers of health care quality (Spertus et al). 2002;143:145-50

Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program (National Heart Attack Alert Program Coordinating Committee). 2002;143:777-89

Is more better? (Nash and Jollis). 2002;143:745-7 (Editorial)

**Quality of life**

Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHEUS (Eplerenone's neuroHormonal Efficacy and Survival Study) (Spertus et al). 2002;143:656-62

Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation (Dorian et al). 2002;143:984-90

**R****Radiocontrast media; see Contrast media****Radionuclide imaging**

Comparison of 2-dimensional echocardiography and myocardial perfusion imaging for diagnosing myocardial infarction in emergency department patients (Kontos et al). 2002;143:659-67

**Radiotherapy**

Centered versus noncentered source for intracoronary artery radiation therapy: a model based on the Scripps Trial (Arbab-Zadeh et al). 2002;143:342-8

Impact of geographic miss on adjacent coronary artery segments in diffuse in-stent restenosis with -radiation therapy: angiographic and intravascular ultrasound analysis (Hong et al). 2002;143:327-33

**Rehabilitation**

Effects of cardiac rehabilitation and exercise training on autonomic regulation in patients with coronary artery disease (Lucini et al). 2002;143:977-83

Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease (Church et al). 2002;143:349-55

**Renal circulation**

Enolopamine mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy (Tumlin et al). 2002;143:894-903

Renal artery stenosis: a cardiovascular perspective (Vashist et al). 2002;143:559-64 (Curriculum cardiol.)

**Renal failure, chronic; see Kidney failure, chronic****Reperfusion; see Myocardial reperfusion****Restenosis; see Coronary restenosis****Revascularization, myocardial; see Myocardial revascularization****S****Safety**

Assessment of the safety and efficacy of the DUETT vascular hemostasis device: final results of the Safe and Effective Vascular Hemostasis (SEAL) trial (SEAL Trial Study Team). 2002;143:612-19

The Low Energy Safety Study (LESS): rationale, design, patient characteristics, and device utilization (Mann et al). 2002;143:199-204 (Trial design)

Low settings of the ventricular pacing output in patients dependent on a pacemaker: are they really safe? (Schuchert et al). 2002;143:1009-11

**Shock, cardiogenic**

Cardiogenic shock complicating acute myocardial infarction in elderly patients: does admission to a tertiary center improve survival? (Berger et al). 2002;143:768-76

**Sildenafil citrate**

Effects of sildenafil citrate (Viagra) on cardiac repolarization and

on autonomic control in subjects with chronic heart failure (Piccirillo et al). 2002;143:703-10

#### **Smoking**

Effect of cigar smoking on endothelium-dependent brachial artery dilation in healthy young adults (Santo-Tomas et al). 2002;143:83-6

Morphologic changes in the microcirculation induced by chronic smoking habit: a videocapillaroscopic study on the human labial mucosa (Lova et al). 2002;143:e2

#### **Sodium**

Potential contributing factors to noncompliance with dietary sodium restriction in patients with heart failure (Neily et al). 2002;143:29-33

The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure (Ferreira et al). 2002;143:391-7

#### **Spiritual therapies**

Study of the Therapeutic Effects of Intercessory Prayer (STEP): study design and research methods (Dusek et al). 2002;143:577-84 (Trial design)

#### **ST segment; see *Electrocardiography***

#### **Statins; see *Antilipemic agents***

#### **Stents**

Coronary stent implantation in patients older than 75 years of age: clinical profile and initial and long-term (3 years) outcome (Muñoz et al). 2002;143:620-6

Could direct stenting reduce no-reflow in acute coronary syndromes? A randomized pilot study (Sabatier et al). 2002;143:1027-32

Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation (Seyfarth et al). 2002;143:118-23

Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists (Mazur et al). 2002;143:594-601

Impact of geographic miss on adjacent coronary artery segments in diffuse in-stent restenosis with radiation therapy: angiographic and intravascular ultrasound analysis (Hong et al). 2002;143:327-33

Natural history of small and medium-sized side branches after coronary stent implantation (Poerner et al). 2002;143:627-35

Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy (Gibson et al). 2002;143:106-10

Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial (Berger et al). 2002;143:841-6

#### **Stress test; see *Echocardiography, stress; Exercise test***

#### **Study of the Therapeutic Effects of Intercessory Prayer (STEP)**

Study of the Therapeutic Effects of Intercessory Prayer (STEP): study design and research methods (Dusek et al). 2002;143:577-84 (Trial design)

#### **SYNergy trial**

The SYNERGY trial: study design and rationale (SYNergy Executive Committee). 2002;143:952-60 (Trial design)

## **T**

#### **Tachycardia, supraventricular**

Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response (Page et al). 2002;143:643-9

#### **Tachycardia, ventricular**

Effect of surgical revascularization in patients with coronary artery disease and ventricular tachycardia or fibrillation in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry (Cook et al). 2002;143:821-6

Transmyocardial laser revascularization and left ventricular reduction surgery affect ventricular arrhythmias and heart rate variability (Brunner et al). 2002;143:1012-6

#### **Terbogrel**

Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension (Langenberg et al). 2002;143:e4

#### **Testosterone**

Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease (Thompson et al). 2002;143:249-56

#### **Thallium**

Assessment of cardiac viability by thallium 201 redistribution and dobutamine echocardiography (Zamorano et al). 2002;143:157-62

#### **Thrombosis**

Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment (Babitt et al). 2002;143:205-16 (Curriculum cardiol.)

Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial (Berger et al). 2002;143:841-6

#### **Thromboxane A2**

Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension (Langenberg et al). 2002;143:e4

#### **Thyroid hormones**

Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism (Dernellis and Panaretou). 2002;143:718-24

#### **Ticlopidine**

Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial (Berger et al). 2002;143:841-6

#### **Tomography, x-ray computed**

Coronary calcium scanning adds incremental value to patients with positive stress tests (LaMont et al). 2002;143:861-7

Electron beam tomography and angiography: sex differences (Budoff et al). 2002;143:877-82

#### **Trandolapril**

Acute blood pressure response to trandolapril and captopril in patients with left ventricular dysfunction after acute myocardial infarction (Weber et al). 2002;143:313-18

#### **Tranilast**

The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2) (Tamai et al). 2002;143:506-13

#### **Treatment failure**

Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes (Cohen et al). 2002;143:63-9

#### **Treatment outcome; see *Outcome assessment (health care)***

#### **Treatment refusal**

Potential contributing factors to noncompliance with dietary sodium restriction in patients with heart failure (Neily et al). 2002;143:29-33

#### **Tropponin I**

Chronologic electrocardiographic changes in patients with hypertrophic cardiomyopathy associated with cardiac troponin I mutation (Shimizu et al). 2002;143:289-93

Septal wall thinning and systolic dysfunction in patients with hypertrophic cardiomyopathy caused by a cardiac troponin I gene mutation (Shimizu et al). 2002;143:690-5

#### Troponin T

Cardiac troponin T levels are associated with poor short-and long-term prognosis in patients with acute cardiogenic pulmonary edema (Perna et al). 2002;143:814-20

The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy (Diderholm et al). 2002;143:760-7

## U

#### Ultrogra rapid platelet-function assay

The Ultrogra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy (Wheeler et al). 2002;143:602-11

#### University of Michigan

Acute myocardial infarction in the young—the University of Michigan experience (Doughty et al). 2002;143:56-62

#### Uric acid

Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy (Cicoira et al). 2002;143:1107-11

## V

#### Vasopeptidase inhibitors

Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial (Eisenstein et al). 2002;143:1112-17

#### Ventilation, pulmonary; *see* Pulmonary ventilation

#### Ventricular dysfunction, left

Acute blood pressure response to trandolapril and captopril in patients with left ventricular dysfunction after acute myocardial infarction (Weber et al). 2002;143:313-18

Deceleration time of early filling in patients with left ventricular systolic dysfunction: functional and prognostic independent value (Morales et al). 2002;143:1101-6

Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations (Groenning et al). 2002;143:923-9

Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy (Cicoira et al). 2002;143:1107-11

Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates (Warraich et al). 2002;143:1076-84

Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction (Jeejeebhoy et al). 2002;143:1092-100

Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction (Kurisu et al). 2002;143:448-55

#### Ventricular fibrillation

Effect of surgical revascularization in patients with coronary artery disease and ventricular tachycardia or fibrillation in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry (Cook et al). 2002;143:821-6

Transmyocardial laser revascularization and left ventricular reduction surgery affect ventricular arrhythmias and heart rate variability (Brunner et al). 2002;143:1012-6

#### Ventricular function, left

Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study (Tang et al). 2002;143:854-60

Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction (Inoue et al). 2002;143:790-6

Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging (Dubach et al). 2002;143:676-83

Impact of body iron status on myocardial perfusion, left ventricular function, and angiographic morphologic features in patients with hypercholesterolemia (Say et al). 2002;143:257-64

Influence of left ventricular size and hemodynamics on the systolic longitudinal myocardial Doppler velocity response to stress (Cain et al). 2002;143:169-75

Left ventricular function in atrial fibrillation during overdrive pacing (Vankawala et al). 2002;143:827-32

Losartan treatment and left ventricular filling during volume loading in patients with dilated cardiomyopathy (Spinelli et al). 2002;143:433-40

Treatment of acromegaly improves myocardial abnormalities (Vianna et al). 2002;143:873-6

#### Ventricular hypertrophy, left; *see* Hypertrophy, left ventricular

#### Ventricular premature complexes

Prevalence of premature ventricular contractions in a population of African American and white men and women: the Atherosclerosis Risk in Communities (ARIC) Study (Simpson et al). 2002;143:535-40

#### Ventricular remodeling

Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide (Nilsson et al). 2002;143:696-702

#### Ventricular tachycardia; *see* Tachycardia, ventricular

#### Viagra; *see* Sildenafil citrate

## W

#### Whites; *see* Ethnic groups

#### Women

Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease (McCubbin et al). 2002;143:711-17

Electron beam tomography and angiography: sex differences (Budoff et al). 2002;143:877-82

Large brachial artery diameter is associated with angiographic coronary artery disease in women (Holubkov et al). 2002;143:802-7

Typical symptoms are predictive of acute coronary syndromes in women (Milner et al). 2002;143:283-8

#### Worcester Heart Attack Study

Use of the invasive management strategy for patients with non-Q-wave myocardial infarction: an observational database report from the Worcester Heart Attack Study (Dauerman et al). 2002;143:1033-9

#### Workload

Prognostic impact of workload in patients with congestive heart failure (Huelsmann et al). 2002;143:308-12

